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Parathormone determination in the Clinical Laboratory: biochemical, analytical and 
clinical aspects. 
 
Abstract. 
 
The aim of our work was to provide comprehensive data to the study of the Parathyroid 
hormone (Parathormone, or PTH). The first part of the manuscript concerns the “laboratory” 
aspects of PTH determination. We thus studied the stability of the peptide when stored at 
different temperatures (pre-analytical phase). From an analytical point of view, we compared 
different methods for PTH determination and the impact of any change in PTH determination 
for the follow-up of the hemodialyzed patients. We also studied some analytical interferences 
and provided a validation strategy that takes into consideration these interferences. Finally, 
for the post-analytical phase, we established the reference range of PTH with two different 
methods. We provided guidelines which could help laboratories to establish their own 
reference range for PTH and studied the clinical impact of applying this newly established 
reference range in the daily routine. 
The second part of the manuscript is more dedicated to the “clinical” aspects of PTH 
determination. We focused on the problems encountered when determining PTH in CKD and 
hemodialyzed patients. We also studied different bone markers in these patients to see if one 
of them could, in the future, replace PTH for the follow-up of these patients. Finally, we 
studied the “amino-PTH”, a newly discovered form of PTH, in a large population of patients 
suffering from parathyroid cancer. We thus presented the 
onndgenerati
onrdgenerati
2
3  PTH ratio as a 
potential marker of parathyroid carcinoma.  
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Détermination de la PTH au Laboratoire de Chimie clinique : aspects biochimiques, 
analytiques et cliniques. 
 
Résumé. 
 
Notre travail est consacré à l’étude de l’hormone parathyroïdienne (parathormone, PTH). La 
première partie de l’ouvrage concernera plus particulièrement les aspects “laboratoire” du 
dosage de la PTH. Ainsi, d’un point de vue pré-analytique, nous avons étudié la stabilité du 
peptide lorsqu’il était conservé sous différentes conditions de température. D’un point de vue 
analytique, nous avons comparé différentes méthodes de dosage de la PTH et étudié l’impact 
d’un changement de méthode sur le suivi longitudinal des patients dialysés. Ensuite, nous 
avons étudié différentes interférences analytiques et nous avons proposé une stratégie qui 
permet de prendre en compte ces interférences lors de la validation biologique des résultats. 
Enfin, d’un point de vue post-analytique, nous nous sommes interrogés sur la meilleure façon 
de définir la « population de référence » pour établir les valeurs de référence de la PTH. Nous 
avons ainsi établi les valeurs de référence pour deux méthodes analytiques différentes et 
étudié l’impact de l’utilisation de nos propres valeurs de référence par rapport à celles 
fournies par le fabricant des kits de dosage.  
La deuxième partie de l’ouvrage est consacrée aux aspects plus « cliniques » du dosage de la 
PTH. Nous nous sommes ainsi consacrés aux difficultés rencontrées lors du dosage de la PTH 
chez les patients insuffisants rénaux et dialysés. Nous avons également étudié la possibilité 
d’utiliser d’autres marqueurs osseux chez ces patients afin de voir si l’un d’entre eux pourrait, 
éventuellement, remplacer la PTH pour le suivi de ces patients. Enfin, nous avons étudié l’ 
« amino-PTH », une forme de PTH récemment découverte dans une importante population de 
patients souffrant de carcinome parathyroïdien sévère. Nous proposons ainsi d’utiliser le 
rapport  
".2.."
".3.."
générationèmedePTH
générationèmedePTH  comme marqueur tumoral du cancer parathyroïdien.  
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“The first telescope opened the heavens; the first microscope 
opened the world of the microbes; radio-isotopic 
methodology, as exemplified by RIA, has shown the potential 
for opening new vistas in science and medicine” 
 
 
Rosalyn S Yalow, 
Nobel Prize Lecture,  
8th December 1977 
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A. PARATHORMONE AND THE PARATHYROID GLANDS 
 
 
 
 
RHINOCEROS UNICORNIS 
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1.  Discovery of the parathyroid glands 
 
In May 1834, the Zoological Society of London purchased a Great Indian Rhinoceros 
(Rhinoceros unicornis). The animal died in November 1849 and its carcass was offered to Sir 
Richard Owen (1804–1892), Professor and Conservator of the Museum in the Royal College 
of Surgeons of England 1. The dissection of the 2 tons animal took place in the winter months 
of 1849 to 1850. The notes of the dissection, published in 1862, include the rhinoceros’s last 
days as recorded in the Head-Keeper’s minute book 2. 
In his detailed description of the anatomy, Owen observed ‘a small compact yellow glandular 
body attached to the thyroid at the point where the vein emerged’: this structure is now 
known as the parathyroid gland.  
Even if Owen is the first one to have described the parathyroid glands, Ivar Viktor Sandström 
from Sweden (1852–1889) is credited for the discovery and the name of the glands. This 
medical student was employed in the Department of anatomy in the University of Uppsala 
when he observed interesting structures in a dog’s neck. In 1880, he wrote: 
‘I encountered on the thyroid of a dog a small hardly hemp-seed sized structure which was 
included in the same capsule as the thyroid but distinguished itself from it by a brighter 
colour. A superficial examination revealed an organ of a structure entirely different from that 
of the thyroid and particularly amply vascularised, because of which I considered it probable 
that here a vascular gland had been encountered, analogous to the carotid glands’3. 
 He then identified the organ in other animals before proceeding to human anatomy and to 
find it in the first individual examined, ‘found on both sides of the inferior border of the 
thyroid an organ of the size of a small pea which judging from its exterior, did not appear to 
be a lymph gland, or an accessory thyroid gland and which upon histological examination 
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showed a rather peculiar structure’. He named these new structures glandulae 
parathyroidae. 
The relevance of the Sandström’s discovery remained unappreciated until Eugene Gley 
(1857–1930), Professor of Physiology and Endocrinology at the Collège de France in Paris, 
understood the endocrine function of the parathyroid glands. In 1891, he observed that tetany 
and death caused by experimental thyroidectomy in dogs occurred only if the excised material 
included the glands described by Sandström 4. It was also in 1891 that the famous German 
pathologist Friedrich Daniel Von Recklinghausen (1833-1910) described osteitis fibrosa 
cystica, a disease associated with recurrent fractures of several bones with negligible trauma 
and ‘bending’ of the long bones with extensive fibrosis, cysts and brown tumours 5. However, 
he was not aware that this disease was associated with an excessive secretion of 
parathormone.  
In 1907, Jakob Erdheim (1874-1937) a young pathologist working in Vienna noted the 
relation between the function of the parathyroid glands and the structure of bone and teeth 6. 
However, the central role played by the parathyroid glands in calcium metabolism was not yet 
appreciated until 1908. At that time, the correlation between parathyroidectomy or 
parathyroid insufficiency and convulsive symptoms, spasmodic states or eclampsy had been 
established 7. In 1901, Jacques Loeb (1859-1924), a German biologist working in Chicago, 
noticed that “the muscle itself contains calcium salts, and we consider it likely that these 
calcium salts might help in preventing contractions” 8. This led two famous scientists, the 
Canadian William G. MacCallum (1874-1944), and the Swiss Carl Voegtlin (1879-1960), 
working together at the Johns Hopkins Hospital as respectively Professor of Pathological 
Physiology and Professor of Pharmacology to set that the function of the parathyroid glands 
was connected with calcium metabolism 9, 10. 
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In 1915, Friedrich Schlagenhaufer (1866–1930), Professor of pathology in Vienna, suggested 
that an enlarged parathyroid might be the cause of bone disease and not the result of it. He 
presented two patients with osteomalacia each of whom was found to have a single 
parathyroid tumour at necropsy 11. 
 Ten years later, Felix Mandl (1892–1957), from the University of Vienna was the first one to 
remove a parathyroid tumour 12.  Under local anaesthesia, he removed a ‘yellowish-brown 
almond shaped tumour’ measuring 25×15×12 mm from the left inferior area behind the 
thyroid gland of a patient suffering from severe von Recklinghausen’s disease, with 
immediate improvement. Indeed, this impotent patient (a 1914-1918 soldier that had been 
invalidated by tuberculosis in the trenches) recovered rapidly and within a few days, his blood 
and urine calcium content lowered considerably and his bones recalcified.  
  PTH and the parathyroid glands 
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2. Discovery of the parathyroid hormone 
 
Adolph Melanchton Hanson (1888-1959), an American surgeon from Faribault (Minnesota), a 
little city located in the south of Minneapolis, was trying to extract the active substance from 
parathyroid glands. Using hydrochloric acid, he extracted from bovine parathyroid glands a 
substance that could treat experimental tetany, raise the calcium levels after 
parathyroidectomy in dogs, and cause osteoporosis if given over a period of time. He 
published these observations in 1923 and in 1924 13, 14.  
However, he was not the only one to work on this field and had a serious competitor. James 
Bertram Collip (1892-1965) was Professor of Biochemistry at Edmonton University, in 
Canada. He had already been involved in the discovery of insulin and awarded the Nobel 
Prize for this discovery (together with Macleod, Banting and Best) in October 1923. Based on 
his “insulin” experience, he postulated that the extracts of parathyroid glands, which caused 
tetany, produced a hormone. With hot hydrochloric acid, he extracted a crude substance from 
parathyroid glands, and by injecting this extract to parathyroidectomized dogs, he was able to 
maintain them alive for several months. Thus, he proved that his extract could serve as 
replacement therapy, but he went further and treated patients suffering from tetany with 
success in a clinical trial of his preparation. Collip had kept good contacts with Eli Lilly since 
their collaboration in the commercialization of insulin for diabetes mellitus treatment. Even if 
Hanson had been the first to isolate parathormone and to contact Eli Lilly, the director of 
research of the company urged Collip to publish his results and to make a mention to 
Hanson’s papers 15.    
  PTH and the parathyroid glands 
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B. DETERMINATION OF THE PARATHYROID HORMONE 
 
In 1963, Solomon Berson and Rosalyn Yalow from the Bronx Veterans Administration 
Hospital of New-York published the description of the first immuno-assay for parathyroid 
hormone 16. The PTH standard had been obtained from bovine parathyroid glands and 
labelled with131I. They had obtained their anti-PTH antibodies by injecting the bovine 
parathyroid glands extracts in guinea pigs and rabbits at intervals of 2-4 weeks. With their 
technique, they were able to detect endogenous PTH in plasma samples obtained from 2 
subjects with hyperparathyroidism, but not in plasma obtained from 9 subjects with 
hypoparathyroidism. They also detected PTH in random samples obtained from subjects 
without known parathyroid disease. Rosalyn Yalow (Solomon Berson had passed over at that 
time) was awarded the Nobel prize in 1977 for her contribution to the development of RIA for 
peptide hormones. 
In 1968, Reiss and Canterbury developed an assay using anti-PTH antibodies obtained by 
injecting bovine PTH to chickens 17. This assay presented a high affinity and a strong cross-
reactivity with human PTH. They used an arbitrarily selected hyperparathyroid serum derived 
from a uremic subject with severe secondary hyperparathyroidism as a standard, which was 
assigned a concentration of 1000 picograms equivalents per millilitre. With this kit, they 
showed that in a “normal” population, the PTH ranged between 2 and 54 and was not 
measurable in hypoparathyroid patients. In the hyperparathyroid group, the lowest assay value 
of PTH was 100 whereas it reached 2000 in a patient with hypercalcemic crisis resulting from 
carcinoma of a parathyroid gland 18. 
In the early seventies, many laboratories used to perform PTH determination with what we 
call now the “first generation” assays. These radio-immunoassays (RIA assays) used a single 
anti-PTH antibody that was either produced by the analytical laboratory himself (by 
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immunization of an animal - generally a rabbit - with the peptide) or a commercially available 
antibody.  
The peptide (from bovine origin) was bought in specialized societies and labelled with 125I. 
The samples were incubated with the anti-PTH antibody for 4 days at 4°C. Then the 125I 
marked PTH was added and a second incubation of 3 days at 4°C occurred. This second 
incubation resulted in a competition for the anti-PTH antibody between the marked PTH and 
the patient’s PTH. Then a second antibody (a sheep anti-rabbit IgG) precipitated the complex 
“PTH of the patient or marked PTH-anti-PTH antibody”. This precipitate was washed and 
counted with a gamma-counter. The “counts” were inversely proportional to the PTH 
concentration of the patient (Figure 1). 
  
Figure 1:  a typical RIA curve. 
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At that time, in Liège, PTH determination was performed by the Laboratoire de Radio-
immunologie de la Faculté de Médecine (Dr Heynen and Prof. Franchimont). The antibody 
used was the antiserum 211/32 bought from Wellcome Laboratories at the final dilution of  
000.400
1 . This antibody was able to recognize the native (1-84) molecule and the fragments 
that contained the amino-terminal sequence (1-34). In 1977, our predecessors published a 
non-equivocal paper entitled “La Parathormone sérique: problèmes récents” (sic) 19. Indeed, 
these “first generation” assays were important for a better comprehension of the 
phosphocalcic metabolism and helped for the diagnosis of primary and secondary 
hyperparathyroidism. However, they suffered from important interferences due to the 
“carboxy-terminal fragments” (COOH-fragments), which were PTH fragments of 
approximately 7000 kD. This was a consequence of the lack of a total specificity of the 
antiserums used for the aminoterminal sequence. These COOH-fragments were already 
known at that time to have a longer half-live than the native (1-84) peptide and the cross-
reactivity of the antiserum and the COOH-fragments explained partially the discrepancies in 
PTH results observed between different laboratories.  
The interference of the COOH-fragments was especially important in hemodialyzed patients. 
In these patients, PTH concentrations measured with these assays were always greatly 
increased. This was even the case in certain patients clearly identified by bone biopsy as 
suffering from low turnover bone disease, a condition associated with a defect in PTH action. 
Furthermore, these assays had a poor analytical sensitivity in the low concentrations of the 
peptide, which did not really allowed the discrimination between low- and normal-levels 20. 
In 1974, at its 26th meeting, the Expert Committee on Biological Standardization of the World 
Health Organization (ECBS, WHO), remarked that the different PTH immunoassays 
presented a growing interest for different clinical purpose. They thus asked the National 
Institute for Biological Standards and Control (London), to obtain material of human origin 
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which could serve as an international reference preparation (IRP). In December 1978, a 
nominal amount of 150 μg of hPTH, stated to be more than 95% pure, was donated to WHO 
as a proposed IRP. Ampoules, labelled 79/500 were prepared in 1981, evaluated in a 
multicentric study and became the International Reference Preparation (IRP) of Parathyroid 
Hormone, Human, for Immunoassay 21. The results of this study emphasized the 
heterogeneity of the results obtained in the different home-made or commercially available 
immunoassay systems used at that time. Due to mainly lack of stability and reconstitution 
problems, the WHO standard has really never been used. 
 
In 1987, Nichols launched an Immunoradiometric (IRMA) kit called “Allegro” 22. This 
immunoradiometric assay (IRMA) used a pair of different antibodies: a capture antibody 
coated to a plastic bead was directed against the (39–84) portion of the PTH molecule, and a 
125I labelled antibody recognized the (13–24) portion of the peptide. 
This “sandwich” assay was thus not influenced any more by the COOH-terminal or mid-
fragments which were measured with the first-generation assays. This “second-generation” 
assay kit and the ones that followed were globally called ‘‘intact’’ PTH assays as they were 
thought to measure only the full-length (1–84) PTH.  
During the following years, several similar assays, either IRMA or fully automated 
chemiluminescent assays became available on the market. In Liège, the Allegro assay 
replaced the “first-generation” PTH. Then, we used an “intact” PTH from Incstar, a company 
bought later by DiaSorin. The Incstar/DiaSorin IRMA was used until 2004, as we decided to 
move to the Liaison (DiaSorin), a chemiluminescent automate.  
Some commercially available “intact PTH” assays use an anti-N-terminal antibody directed, 
like the Allegro assay, towards the proximal (13–24) portion of the hormone, whereas others, 
like Roche Elecsys intact PTH assay, recognize a more distal epitope, in the (26–32) portion.  
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Even if these second generation kits gave results much more consistent with the clinic, they 
were rapidly shown to present some limitations. Indeed, several reports suggested that they 
overestimated the degree of secondary hyperparathyroidism in CRF patients 23, 24. Some of 
these patients presented elevated “intact” PTH concentrations whereas they presented 
histological features of low turnover bone disease…   
These apparent discrepancies were explained in 1998, after the demonstration that several 
‘‘intact’’ PTH assays recognized, with various cross-reactivities (from approximately 50% to 
100%), a PTH molecule different from the (1–84) PTH, which co-eluted in HPLC with a 
synthetic (7–84) PTH fragment 25. This fraction was then called the “non-(1-84) PTH” or, 
more generally, “(7-84) PTH” (Figure 2). 
  Determination of PTH 
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Figure 2: HPLC profiles of circulating I-PTH in two pools of uremic samples (top, ~60 
pmol/L; bottom, ~100 pmol/L).  
Assays: Nichols (—), Incstar (... .), and DSL (- - -). Left arrow, hPTH(7–84) standard; right 
arrow, hPTH(1–84) standard. From Lepage et al 25. 
We can see from this graph that, when the substrate caught by the antibodies used in the 
“intact” PTH kits is processed in chromatography, two different moieties are observed, (1-
84) PTH and a fraction that migrates with (7-84) PTH. 
 
 
 
 
 
In 1999, the first “third-generation” PTH assay was developed by Scantibodies Laboratories 
26. This IRMA, called “Whole PTH assay” or “Bio-intact PTH”, uses an anti-COOH-
terminal antibody similar to those of the ‘‘intact’’ PTH assays, but an anti-N-terminal 
antibody directed against the very first amino-acids (1 to 4) (Figure 3). Thus, this IRMA does 
not measure the ‘‘non-1–84’’ PTH fragments anymore. This kit does neither cross-react with 
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the N-truncated fragments. With the help of this kit, it became possible to evaluate the amount 
of the non-(1-84) PTH. Indeed, by removing the value of the “whole” PTH from the “intact” 
PTH (if this intact PTH cross-reacts at 100% with the non-(1-84)PTH), we obtain the amount 
of the  non-(1-84) PTH present in the serum of the patient.  
PTHwholeactPTHPTHnon ""int")841( −=−−  
 
 
Figure 3: on the left side of the picture, we see that, in the 2nd Generation of PTH kits, the 
2nd antibody catches (1-84) PTH and (7-84) PTH, whereas on the right side of the picture, 
the 2nd antibody of the 3rd generation kits is specific for the first four aminoacids of the 
peptide, thus not interfering anymore with the (7-84) PTH. © Scantibodies 
 
 
Recently, it has been shown that a N-terminal molecular form of parathyroid hormone 
(amino-PTH), a PTH possibly phosphorylated on the serine in position 17, was overproduced 
in parathyroid carcinoma 27, 28 and in rare cases of severe primary hyperparathyroidism 29, 
leading to an inversion of the 
onndgenerati
onrdgenerati
2
3 PTH ratio.   
Indeed, amino-PTH cross reacts with the antibodies used in the 3rd generation PTH (“whole” 
or “complete’ PTH), which are directed against the first four amino-acids of the peptide, but 
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not with the antibodies used in the 2nd generation kits (“intact” PTH). It should also be noted 
that the Roche Elecsys kit (a second generation PTH assay that uses an antibody directed 
against a more distal part of the peptide) also presents an interference with amino-PTH 20. In 
normal individuals, amino-PTH represents approximately 10% of the circulating PTH 30. 
Thus, the 
onndgenerati
onrdgenerati
2
3  PTH ratio should always be <1 because the large non-(1-84) 
fragments detected with the 2nd generation (and not the 3rd) kits represent a larger proportion 
of the circulating PTH than amino-PTH does. We will see later the potential interests of 
amino-PTH in the diagnosis of parathyroid carcinoma. 
The different PTH moieties recognized by the different PTH generation kits are summarized 
in Table 1. 
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Table 1: main PTH circulating fragments and whether they are measured by the various 
PTH assay-generations 
 
 1st generation assays 2nd generation assays 3rd generation assays 
Most common 
identifications 
C-PTH assays, 
Mid-PTH assays 
“Intact” PTH assays Whole  PTH assay, 
Ca-PTH assay, 
BioIntact PTH assay 
Methodology RIA 
(competition assays) 
IRMA, 
Chemiluminescence,  
(sandwich assays) 
IRMA  
(sandwich assays) 
(1-84) PTH 
recognition? 
Yes Yes Yes 
Non-(1-84) 
recognition? 
Yes Yes (with various 
cross-reactivity) 
No 
C-terminal fragments 
recognition? 
Yes No No 
Amino-PTH 
recognition? 
Yes Depends on the 
epitope of the N-
terminal antibody. 
No if the epitope is 
proximal (13-24), 
Yes if the epitope is 
distal (26-32) like 
Roche Elecsys PTH 
Yes 
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C. ROLE, STRUCTURE AND METABOLIZATION OF 
PARATHORMONE  
 
 
 
 
FIGURE 4: THE PARATHORMONE  
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Parathormone, together with 1,25(OH)2 vitamin D, plays a key role in the phosphocalcic 
regulation. Even if the study of the phosphocalcic metabolism is not the main purpose of this 
work, some essential information on the physiology of calcium and phosphate, as well as their 
regulation, is necessarily before going any further. 
 
1. Calcium. 
 
Our organism contains approximately 25000 mmol (1000 g) of calcium. The majority of 
calcium is contained in the bones (more than 99%) whereas less than 1% can be found in the 
extracellular fluids.  
Calcium is normally present in our alimentation and the needs are approximately of 1 gram 
per day. Thirty to 35% of this alimentary calcium is absorbed through the small intestine, 
under the influence of 1,25(OH)2 vitamin D or passively. In normal situation, the sum of the 
absorbed calcium corresponds to the amount of calcium eliminated in the urine through the 
kidneys and the total balance for calcium is null. However, this kidney elimination has some 
limits. Indeed, under physiological normal conditions, it is quite difficult with a Western diet 
to eliminate less than 100 mg/day of calcium in the urine 31. Thus, in the situations where the 
alimentation contains less than 600 mg/day (which is quite frequent in our lifestyle) or when 
there is an alteration of the intestinal absorption of calcium, the neat calcium balance becomes 
negative. 
Bone remodelling, in young adults, is responsible for the release of approximately 200 mg of 
calcium in the circulation. On the other hand, the bone formation process will also need 
approximately 200 mg in order to mineralize the newly formed bone matrix (Figure 5). 
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Figure 5: Calcium flux in a normal adult having a diet containing the recommended 
amount of calcium. Personal illustration. 
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The only “active” and regulated form of calcium is the ionized calcium (Ca++), which 
represents 50 to 55% of the total circulating calcium. However, due to analytical and 
preanalytical problems, total calcium, and not Ca++, is generally measured. One should then 
keep in mind that in some conditions, where pH or albumin variations are observed, the total 
calcium will not reflect the true value of Ca++. Some formulas exist to “correct” the total 
calcium, but with imperfections (particularly in hemodialyzed patients), as we and others have 
shown 32, 33.  
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2. Phosphate 
 
Our organism contains approximately 500 grams of phosphate, mainly found in bones (85%). 
Fourteen percent of phosphate is present in the intracellular fluid and 1% in the extracellular 
fluid (ECF). In the ECF, one third of the phosphate circulates as a free form, weakly linked to 
proteins, calcium or magnesium (Figure 6). The total balance of phosphate is null in normal 
adults, positive in children and negative in the elderly. The total amount of phosphate found in 
the diet ranges approximately from 800 to 2000 mg/day. An important part of this phosphate 
(approximately 70%) is absorbed in the duodenum and in the jejunum, via two mechanisms. 
The first one is a passive, unregulated and non-saturable mechanism, and depends only on the 
phosphate gradient between the intestinal lumen and the interstitial liquid. The other 
(saturable and regulated) mechanism relies on the sodium/phosphate cotransporter Npt2b. In 
situations where high levels of phosphate are present in the intestine, the passive mechanism 
is predominant whereas if the quantity of phosphate is low in the diet, the active mechanism 
will be preponderant. 
In normal situations, the quantity of phosphate coming from the intestine corresponds to the 
one that is eliminated by the kidneys. Kidneys play the central role in the phosphate 
regulation, as the intestinal absorption of phosphate from diet is poorly regulated and bones 
do not significantly participate to its regulation 34.       
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Figure 6: Phosphorus flux in a normal adult receiving a diet containing the recommended 
amount of phosphate. Personal illustration. 
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3. The phosphocalcic regulation.  
 
In normal individuals, the calcemia is remarkably stable (intra-individual variation <2%, 
according to Westgard and Ricos). This is due to the different fluxes of calcium between 
bone, kidneys and the extracellular fluids. Briefly, in fasting conditions, the sum of calcium 
eliminated by the kidneys is compensated by an equal quantity of calcium liberated by the 
bone. This process is independent from the bone-remodelling process, which is a slow 
phenomenon, not adapted to the correction of a quick calcium variation. Rapid release of 
calcium from bone implicates another cellular mechanism (via the osteocytes, probably) and 
affects only the newly mineralized bone. After the meal, and in normal situations, the total 
amount of calcium that had been lost by the bones to maintain the calcemia is completely 
compensated. 
As already said, calcium regulation is under the control of 2 hormones, PTH and 1,25(OH)2 
vitamin D. Calcium levels are also maintained by the calcium itself, via the Calcium Sensing 
Receptor (CaSR). This (CaSR) is a G-coupled receptor of 1078 amino acids which consists of 
a large N-terminal extracellular domain, seven transmembrane helical domains and an 
intracellular C-tail segment (Figure 7) 35.  
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Figure 7: the Calcium Sensing Receptor. 
 
 
 
This receptor is present in the organs that secrete calcium-regulating hormones (the 
parathyroid glands and the C-cells of the thyroid) and in the target tissues of these hormones 
(renal tubules of the kidney, bone and intestine). It plays a key role in the control, by the 
ionized calcium levels, of PTH secretion and in the renal reabsorption of calcium. 
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Figure 8: central role of the calcium-sensing receptor in the development of secondary 
hyperparathyroidism (from de Francisco AL, Expert Opin Pharmacother 2008). 
 
 
 
PTH acts primarily on kidney and bone where it binds to cells expressing the type 1 
PTH/PTHrP receptor (PTH1R). This G-protein coupled receptor is characterized by seven 
transmembrane domains (Figure 9).  When it binds PTH, the PTH/PTHrP receptor transduces 
its signal through activation of protein kinases A and C pathways 36.  
The very first N-terminal amino-acids of the PTH molecule are indispensable for this 
interaction 37.  
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Figure 9: The PTHR1 receptor, from Mannstadt et al, Am J Physiol Renal Physiol 38 
Schematic shows some of the sites in the PTH-1receptor (thick gray-shaded line) and PTH (or PTHrP) ligand 
(narrower solid line) that have been found by mutagenesis or photochemical cross-linking methods to have 
potentially important roles in ligand binding or receptor function. Receptor amino acids and position number 
correspond to the human PTH-1 receptor sequence. 
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In the kidney, PTH stimulates the reabsorption of calcium in the distal tubule and the activity 
of the 1-alpha hydroxylase in the renal proximal tubule, thus enhancing the synthesis of 1,25 
dihydroxy-vitamin D. This active metabolite of vitamin D increases the intestinal absorption 
of calcium (and phosphorus) and exerts an endocrine feed-back on the secretion of the 
peptide. PTH also decreases the renal reabsorption of phosphate in the proximal tubule (which 
decreases serum phosphate) through the endocytosis of the apical sodium dependant 
cotransporter Npt2a 39.  
In bone, as explained above, PTH can induce a rapid release of calcium from the matrix.  
 
Figure 10: Calcium regulation  
 
 
 
 
At longer term, PTH induces changes in Ca metabolism by its action on osteoblasts and 
indirectly on osteoclasts. Briefly, a continuous production of PTH will stimulate bone 
resorption by enhancing the transformation of pre-osteoclasts into active osteoclasts, through 
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the osteoblasts. Indeed, PTH stimulates the osteoblastic production of the Receptor Activator 
for Nuclear Factor κ B Ligand (RANK-L) together with Interleukin-1 and 1,25 (OH)2-vitamin 
D and inhibits the expression of osteoprotegerin, an inhibitor of the RANK receptor. 
Precisely, this receptor is present on the surface of the pre-osteoclasts and its activation by the 
RANK-L will induce the transformation of pre-osteoclasts into active osteoclasts (Figure 11).  
Figure 11: Schematic action of PTH on osteoclasts via the osteoblasts through the 
RANK/RANKL system. 
 
On the other hand, one should notice that PTH stimulates bone formation, as it helps for the 
recruiting, proliferation and differentiation of the osteoblasts as well as reducing their 
apoptosis. This property is now used in clinical practice for the treatment of osteoporosis 40 
(PTH given on one daily injection).  
Calcitonin, a polypeptide secreted by the C-cells of the thyroid gland also inhibits the bone 
resorption by regulating the number and the activity of the osteoclasts. It is secreted in 
response to serum hypercalcemia and may prevent large oscillations in serum calcium levels. 
However, in comparison to PTH and 1,25(OH)2 vitamin D, the role of calcitonin is minor and 
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measurements of serum calcitonin levels is therefore not useful in the diagnosis of Ca 
homeostasis. 
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4. Synthesis and metabolization of parathormone 
 
The human PTH gene is located on the short arm of chromosome 11 41. 
The peptide is first formed as a large polypeptide that then undergoes two successive 
proteolytic cleavages to yield PTH, the principal form of the hormone stored in and secreted 
from the glands. The peptide is synthesized as a pre-proparathyroid hormone (pre-proPTH) 
containing 115 amino acids (Figure 12). Within 1 min of synthesis, pre-proPTH is cleaved in 
its amino-terminal part and looses 25 amino acids to give the proparathyroid hormone 
(proPTH), an intermediate precursor of 90 amino acids. Pro-PTH is transported to the Golgi 
apparatus in 15 minutes, where a second cleavage of 6 AA in the terminal part occurs, 
resulting in the formation of the 84 amino acids PTH. The purpose and mechanism of the 
successive cleavages are unknown 42, but mutations preventing cleavage in pre-proPTH can 
cause hypoparathyroidism 43, indicating the importance of the signal sequences for a proper 
activity of the peptide. 
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The metabolization of the PTH is performed in the liver by the Kupffer cells. This releases 
different amino-truncated PTH fragments in the circulation. These fragments are generally 
called COOH-terminal fragments because they have kept the carboxyl-terminal part of the 
peptide. 44. 
These fragments:  
- are cleared from the circulation through the kidneys, as PTH itself 45, thus  
accumulating in the blood of patients suffering from chronical renal failure (CRF) 46. 
- were thought to be inactive (we will see in a next chapter that this is not the case).  
- have a higher half-live than the (1-84) PTH.  
Figure12 
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- will have an impact on the activity and the analytical determination of the peptide 
(especially in CRF patients). 
- are not only a degradation product of PTH. Indeed, they are also secreted by the 
parathyroid glands. 
- in normal individuals, account for 15-30% of the total PTH, but in CRF patients, this 
percentage can be as high as 70-80%.   
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In the last years, the role of the Clinical Biologist has changed. Indeed, if he remains the 
“analytical partner” of the Clinician, helping in the diagnosis with results of valuable quality, 
he has now to give much more detailed information on different topics, which are now 
considered to be of crucial importance to obtain reliable results. These points concern  notably 
the pre-analytical phase 47, the reference range of the analytes 48, the analytical interferences 49 
and the extensive validation of the methods. He also has to warn the Clinicians against some 
pitfalls which could lead to erroneous diagnostics. All these requirements are clearly 
requested by the ISO 15189 50, the most recent international quality Guideline dedicated to 
biomedical laboratories. 
Based on this evolution, our aims were to provide comprehensive data to the study of 
Parathormone. The first part of the results will concern the analytical aspects of PTH 
determination. The structure of this part will follow the classical laboratory flow and will be 
divided in “pre-analytical”, “analytical” and post-analytical” aspects.  
For the pre-analytical phase, we studied the stability of the peptide when stored at different 
temperatures and under different conditions. The analytical phase will mainly concern the 
evaluation of different methods for PTH testing and the clinical impact of any change in the 
method for the follow-up of the hemodialyzed patients. We also studied different analytical 
interferences and provided a strategy for the validation of the PTH results that takes into 
account these possible analytical interferences. We will illustrate by clinical cases that these 
interferences can lead to erroneous diagnostics. Finally, for the post-analytical phase, we 
focused on the establishment of the “reference” range of PTH. 
The second part of the results will deal with the clinical aspects of PTH determination.  
The first chapter will concern the hemodialyzed patients and in the second one, we will study 
the amino-PTH in patients suffering from severe parathyroid carcinoma.  
Our work is based on these 9 following  publications: 
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A. STABILITY OF PARATHORMONE IN SAMPLES FROM 
HEMODIALYZED PATIENTS. 
 
 
 
 
Stability of intact parathyroid hormone in samples from hemodyalisis patients.  
Cavalier E, Delanaye P, Carlisi A, Krzesinski JM, Chapelle JP 
Kidney Int 2007; 72:370-2. 
  
Estimation of the stability of Parathormone when conserved at -80°C for a long 
period: influence of the patient, of the method and of the sample type. 
Etienne Cavalier, Pierre Delanaye, Philippe Hubert, Jean-Marie Krzesinski, Jean-
Paul Chapelle, Eric Rozet. CJASN; in press. 
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The ISO 15189 Norm requires that laboratories should perform stability studies of the 
biological parameters. Indeed, this factor is of importance for a good pre-analytical handling 
of the samples. In long-term studies, samples are sometimes stored for long periods at -80°C, 
allowing the determination of the analytes in the same batch. Unfortunately, the question of 
stability is poorly addressed and as we will see, this can have serious consequences on clinical 
decisions. In this chapter, we want to discuss the stability of PTH at different temperatures 
and in different conditions. It will be divided in two parts: the first one will deal with the 
stability of PTH when conserved as serum, EDTA plasma or total whole blood at room 
temperature and -20°C; the second will study the long-term stability of the peptide when 
conserved as plasma EDTA or serum at -80°C. In this last study, we will also show the impact 
of the method (Elecsys and Liaison), and of the patient on the maximum storage time. 
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1. Stability of PTH at Room temperature and -20°C. 
 
Analytical and preanalytical conditions are of importance for a good follow-up of the CKD 
patients. So,we evaluated analytical and preanalytical influences on Roche Elecsys PTH 
determination 51. Our approach was designed to be as close as possible to the hospital real life. 
Two series of blood samples were collected in an interval of a month from 16 hemodialyzed 
patients immediately before starting renal dialysis. All the samples were drawn into two tubes, 
one 5-ml EDTA tube and one gel separator with clot activator tube purchased from Becton-
Dickinson. In all cases, the tubes were filled completely and brought to the laboratory within 
30 minutes. On the first set of samples, drawn in October, we evaluated the stability of PTH 
when stored frozen as serum or EDTA plasma at -20°C. The stability of the ‘frozen’ PTH was 
evaluated after 24 h and 5 days. On the second set of samples, drawn in December, we 
investigated the stability of PTH when conserved in the sample tube as EDTA whole blood or 
clotted blood at room temperature (21°C). The stability of ‘temperate’ PTH was evaluated at 
0, 8, and 24 h. For both series, the reference was the level of the corresponding tube assayed 
directly after centrifugation at 4°C. 
 
Considering the two groups of patients as independent samples, the results obtained on the 
tubes assayed directly after sampling (zero time) did differ neither between October and 
December nor between EDTA and serum sample tubes. The mean percentages of PTH 
degradation under our experimental conditions are illustrated in Figure 13.  
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Figure 13: Mean PTH variations (%) when samples are conserved at room temperature as 
whole EDTA blood and clotted serum for 8 and 24 hours, or frozen aliquots of EDTA 
plasma and serum for 1 and 5 days.   
 
 
 
Our results showed that there was no significant difference in PTH degradation between 
serum and EDTA after 1-day conservation at -20°C (-6.2 and -6.6%, respectively). 
Nevertheless, when samples were kept frozen for 5 days, PTH degradation was more 
important in EDTA aliquots than in serum aliquots (-10.8±2.4 vs. -7.2±2.2%, p=0.0004). On 
the other hand, when samples were conserved at room temperature, PTH in EDTA whole 
blood remained relatively stable (mean loss of activity: -4.1%), whereas its degradation in 
clotted serum was already important after 8 h (-8.4±4.8%) and even more after 24h (-
20.5±10.1%). 
This difference in stability between serum and EDTA tubes was very significant (p<0.0001). 
Clinically, by applying the criterion of the Royal Australasian College of Pathologists Quality 
Assurance Program, 33% of serum samples stored at room temperature failed assurance 
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criteria (<25% difference between the sample and the target) and would have thus lead to a 
diagnostic misclassification. In frozen series and EDTA kept at room temperature, no 
transgression of this quality criterion was observed. 
As previously said, our approach in this first part of the work was designed to be as close as 
possible as the ‘real life’ of a sample tube in a hospital. The samples drawn in October 
mimicked the different options usually faced by a laboratory: immediate assay after reception 
or freezing of the samples for a further determination, usually 24 h to 5 days after reception. 
The goal of the study on the samples drawn in December was to see what happened if the 
tubes were left at room temperature from 8 to 24 h before arriving in the laboratory. This kind 
of ‘pragmatic’ methodology is original. Indeed, reports on PTH stability in serum and plasma 
are sometimes contradictory, due to the great differences in the methodologies used. For 
instance, the definition of the ‘zeropoint’ is, for some authors, a freshly frozen aliquot, 
whereas others consider the sample centrifuged and assayed within 3 h. Moreover, storage 
time at -20°C before analysis is not mentioned, which could let suppose that this parameter is 
of minor or no importance. 
The definition of the term ‘stability’ is not also well defined, as most of the authors let 
degrade PTH in serum or plasma EDTA and not in whole EDTA blood or clotted serum. The 
conclusions of these studies are then only applicable to sample management in laboratories 
and cannot be extrapolated to pre-analytical handling of the tubes in the wards. 
From a strict point of view, it may be difficult to draw conclusions from these studies. 
Nevertheless, we agree that EDTA tubes are preferable in situations where rapid delivery of 
blood to the laboratory cannot be achieved. We have also observed that if PTH was 
considerably more stable in EDTA than serum when left at room temperature, it was not 
completely stable. On the other hand, some authors have shown that, when using the Siemens 
Immulite automate, PTH kept in EDTA tubes was higher (8%) after 3 days at room 
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temperature52. We have also observed such behaviour with the DiaSorin Liaison (data not 
shown). 
The in vitro observation that PTH decline is observed in serum and not in EDTA plasma 
suggests that the increased protease activity may be due to the clotting process. Some authors 
showed that the addition of aprotinin significantly reduced the decline in PTH at 24 h – even 
if there was still a difference with EDTA samples. Others found that an addition of two 
protease inhibitors (aprotinin and leupeptin) eliminated completely the decline of PTH 53. 
We did not find any difference between serum and EDTA plasma at baseline, whereas some 
authors reported significant higher values for EDTA plasma. Teal et al.54 did not find 
differences when they compared PTH stability in serum and EDTA plasma with a third-
generation PTH kit. They made the hypothesis that amino-PTH could be more stable than 
PTH itself. As Roche Elecsys PTH antibodies also recognize amino-PTH, our findings 
reinforce this hypothesis. 
When we compared the stability of PTH after 24 h in the ‘frozen’ EDTA tube with the 
‘temperate’ EDTA tube, we observed that PTH was more stable in EDTA whole blood 
than in EDTA plasma conserved at -20°C. This astonishing observation might be attributable 
to a greater PTH sensitivity to freezing/unfreezing than to PTH degradation by plasmatic 
metalloproteases. However, when we validated the method, we observed that PTH stability 
after four cycles of freezing/unfreezing did not support this hypothesis. 
We have shown here that PTH is not always more stable in EDTA than in serum. Indeed, 
EDTA is preferable when samples are left in a ward or in a practitioner’s office at room 
temperature, but once the sample is treated in the laboratory and kept frozen, PTH is more 
stable in serum than EDTA, compared with a ‘fresh’ determination.  
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Our findings are experimental. We do not know why we observed this difference. On the 
other hand, the greater degradation of PTH observed in serum compared with EDTA plasma 
still remains unexplained.  
In conclusion of this first part, the type of samples used for PTH determination should depend 
on the way laboratories work. On one hand, if a lab has a practice of general practitioners or 
works for a multisite hospital, EDTA tubes conserved at room temperature are better. EDTA 
tubes are also preferable if a lab works in continuous flow. On the other hand, if a lab works 
in batches with automates, as it used to be with immunoradiometric assay series, and keep 
samples frozen before determination, serum tubes are the best choice.  
When taking a decision on the best tube for PTH, one must also take into consideration that 
calcium – which should systematically be assayed together with PTH – can not be performed 
on EDTA tubes... 
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2. Estimation of the stability of Parathormone when 
conserved at -80°C for a long period: influence of the patient, 
of the method and of the sample type. 
 
 
To our knowledge, the stability of PTH at -80°C for a long storage period (1 year or more) 
has never been studied. To know if there is, or not, a significant degradation of PTH when 
samples are stored for a long period, like in studies where a serum or plasma EDTA bank 
have been constituted (for instance  in 55-57), might thus be of importance for the conclusions 
of these studies. The aim of this study was to evaluate the stability of PTH when conserved 
for a long period as serum or plasma EDTA samples at -80°C, and to see if there was an 
influence of the method (Roche Elecsys or DiaSorin Liaison) on the results obtained. 
 
Material and Methods. 
Samples were collected in 16 hemodialyzed patients at 08:00h, immediately before 
commencing renal dialysis. All the samples were drawn into 5-ml EDTA (EDTA) and gel 
separator with clot activator tubes (DRY) purchased from Terumo (Haasrode, Belgium). In all 
cases, the tubes were filled completely and brought to the laboratory within 30 minutes. They 
were centrifuged at +4°C and plasma and serum were immediately aliquoted in cap-closed 
tubes and stored at -80°C. An aliquot was directly assayed on Liaison (DiaSorin, Saluggia, 
Italy) and Elecsys (Roche Diagnostics, Mannheim, Germany) to determine the “baseline” 
values for serum and EDTA plasma. 
For each patient, one aliquot of serum and plasma EDTA was thawed after respectively 1, 3, 6 
and 12 months, vortexed, centrifuged and assayed on the 2 automates. 
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 In our hands, the coefficients of variation obtained with the Roche Elecsys PTH and the 
DiaSorin Liaison are <10% 58.    
 
Data treatment 
All the results were reported as recovery values, that is the ratios of the analyte concentration 
at each storage time to the analyte concentration at time 0. The factors “method” (Elecsys or 
Liaison), “tubes” (Dry or EDTA), “subjects” (n=16) and “time” (in months) were included in 
a linear mixed model to evaluate their effects on PTH concentration. Statistical significance of 
those factors were evaluated using α=0.05. Bootstrap prediction intervals for the linear mixed 
model were also computed when relevant 59. JMP v7 (SAS Institute, Cary, USA) and R v2.8.1 
(CRAN, http://cran.r-project.org) were used for model fitting and evaluation and to compute 
prediction intervals. 
 
Results 
The concentration of PTH was modeled as a linear mixed model of factors “methods”, 
“tubes”, “subjects” and “time” using the following model: 
εγβββγ +++++= 4,4332211,0 xxxxY jj  (Eq. 1) 
where Y is the measured PTH concentration (pg/mL), j,0γ  is the random intercept, j,4γ  is the 
random slope for time  and the iβ ’s (i=1 to 3) are the coefficients of the factors “methods”, 
“tubes” and “subjects, respectively. );0( 2εσε N∝  is the residual error assumed normally 
distributed, );0( 2,0 1γσγ Nj ∝  and );0( 2,4 4γσγ Nj ∝  are also assumed normally distributed and 
account for the variability of all the j=1 to 16 subjects. 
The model adjusted R² equaled 0.9 suggesting a good adequacy of the model fitted: 90% of 
the observed variability of the PTH concentration is explained by the retained factors. 
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Statistical evaluation of the coefficient of the factors showed that the type of the method used 
to analyze the samples is highly significant (p-value<0.0001) as shown in Figure 14. 
Similarly, the type of tube used to collect the sample is also significant (p-value=0.041; 
Figure 14). The time of conservation showed a statistically (p-value=0.002) decreasing slope 
of -2.06 as indicated in Figure 14.  
Due to the significant effect of the factors “method” and “tube”, separate analysis for each 
pair of [“method”;”tube”] was performed to further assess the stability of PTH concentration 
over time using a linear mixed model. For each pair of [“method”;”tube”], time of 
conservation has a significant effect over the concentration of PTH (p-value<0.05). About 
60% of the predicted slopes for each subject were found negative. This finding asserts a non 
negligible degradation of PTH over time at -80°C, although not systematic for all biological 
sources of samples.  
However, in practice, it is not the average of samples coming from different subjects that is 
given as a clinically relevant result, but it is rather the PTH concentration of a single patient 
that is of interest, whoever the patient is. Moreover, the model given by Eq.1, as well as the 
smallest models used to evaluate each pair of [“method”;”tube”] showed that the slope of the 
degradation was subject-dependant. 
Although the average degradation slope is statistically significant and knowing that it is 
variable from one patient to another, this degradation may have a practical implication. The 
question is what impact these slopes do have on the future results that will be obtained when 
thawing a single sample of any subject and analyzing it after 6, 12 or even 24 months of 
storage ? This answer can be effectively answered through a graphical representation and 
using prediction interval methodology 59, 60. Prediction intervals allow to predict where a 
future result can be obtained with a defined probability. Figures 15 a-d show the recovery of 
PTH concentration of each subject obtained during the storage of 16 patients samples for each 
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pair [“method”;”tube”]. Added to these figures are drawn their 95% lower prediction interval 
(bold continuous line). Thus, these prediction limits show where a single result of any 
possible future patient can be obtained in the future at each storage time with 95% probability. 
It is thus evident from these figures, that stable storage of these samples at -80°C is not 
infinite. There is indeed a Maximum Storage Time that should be evaluated. Furthermore, this 
is a requirement for laboratories aiming accreditation such as ISO 17025 61 or ISO 15189 50. 
One effective way to determine this storage time is to add to the graph acceptance limits as 
shown in Figures 15 a-d. These acceptance limits represent the maximum degradation that is 
acceptable. The Maximum Storage Time is defined when this acceptance limit crosses the 
lower prediction interval. Those acceptance limits could be for example the limits chosen for 
assessing the validity of the method, or 2 or 3 times the intermediate precision standard 
deviation of the method. The acceptance limits shown in Figures 15 a-d are settled by 
allowing a degradation of maximum -30%, ie. a minimum recovery of 70%  (dashed line) 62. 
The maximum storage times when using the Liaison method with either Dry tubes or EDTA 
ones  depicted in Figures 15a and 15b are the shortest and are estimated of 9 and 2 months, 
respectively. So samples collected with EDTA tubes should not be stored more than 2 months 
using this type of automate as the degradation will exceed the maximum acceptable level of 
degradation of 30%. By opposite when using the Elecsys method, the maximum storage times 
are of at least 27 months whatever the type of tube used, as shown in Figure 15c and 15d. 
When using the Elecsys automate samples could be stored up to 2 years, still with acceptable 
stability of the PTH. Indeed, the degradation will not exceed the maximum acceptable level of 
-30%. Furthermore, the statistical difference between the two methods has shown here the 
practical implication of such a lack of comparability on the stability of PTH. 
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Discussion. 
We presented here the first study on the conservation of PTH at -80°C for a long period. We 
introduced an original method that allowed us to take into account different parameters, like 
the method used to determine PTH, the kind of tube used for sampling, the length of 
conservation and the patient variability. We were thus able to build a model that explained 
90% of the variability of PTH concentration. We also established a Maximum Storage Time 
for the conservation of the peptide using an original methodology. This Maximum Storage 
Time is an important parameter that should be taken into account in studies where samples are 
kept for a long period at -80°C before processing. Indeed, we have shown that there was a 
systematic degradation of PTH and, moreover, that this degradation was patient-dependant. In 
other words, we will observe degradation in some patient samples, but not in others; it means 
that we will be obliged to be restrictive and use the lowest Maximum Storage Time for the 
limit of conservation. In this way, the patient will be protected against inadequate decisions 
made using the analytical results of the stored samples.  
Another striking point is the impact of the assay method used on the Maximum Storage Time. 
Indeed, we observed a more important degradation with Liaison than with Elecsys. This can 
be explained in two points: firstly, Elecsys recognize, next to the PTH molecule itself, another 
peptide called “amino-PTH” which is not recognized by the Liaison antibodies 28. We and 
others have already hypothesized that this amino-PTH was more stable than PTH itself 51, 54, 
explaining why we observe higher levels with Elecsys. Secondly, it is now well known that C-
terminal fragments accumulate in the serum of hemodialyzed patients 25. These fragments are 
more stable than PTH itself 46. The Liaison is one of the methods that cross-reacts at the lesser 
extent with PTH 7-84, the most representative fragment of the C-terminal fragments. This is 
particularly true, when compared to the Elecsys (see Table IV in  63), which could let us think 
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that the decrease observe with the Liaison, and not the Elecsys, could be due to a degradation 
of the PTH molecule itself.  
 
Conclusion 
Conservation of PTH at -80°C is not infinite, but method and patient-dependant. An 
evaluation of the Maximum Storage Time should be performed to ascertain that the samples 
will present the same reactive profile after conservation for a long period. Only in such a way 
will consistent decisions be made with the results obtained from the analysis of the stored 
samples. 
 
Figure 14: Effect of the factors “method”, “tube” and “time” on PTH concentration. 
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Figure 15 : Prediction of the linear degradation of PTH concentration overt time for each 
pair of [“method”;”tube”]:, The circles and the dotted lines show the evolution of the PTH 
recovery with respect to time point “0 month”. The bold continuous lines are the lower 95% 
prediction limits and the dashed lines are the lower acceptance limits settled at 70% of 
recovery. 
(a) [Liaison; Dry] 
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(b) [Liaison; EDTA], 
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(c) [Elecsys; Dry],  
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(d) [Elecsys; EDTA] 
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B. PTH DETERMINATION IN CHRONIC RENAL FAILURE PATIENTS: NOT AN 
EASY TASK 
 
 
  Comparison of Liaison N-tact PTH (DiaSorin) and N-tact PTH SP IRMA 
(DiaSorin) in hemodialyzed patients.  
  Cavalier E, Delanaye P, Krzesinski JM, Chapelle JP. 
   Clin Chem Lab Med 2005; 43:890-1. 
 
  Analytical validation of the new version of the Liaison N-Tact PTH assay.  
  Cavalier E, Delanaye P, Carlisi A, Krzesinski JM, Chapelle JP.  
  Clin Chem Lab Med 2007; 45:105-7. 
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1.  The K/DOQI clinical practice guidelines for bone 
metabolism and disease in chronic kidney disease: impact of 
the PTH determination on the follow-up of the patients. 
 
Routinely, Nephrologists rely on the generally accepted K/DOQI guidelines for the 
management of the CKD patients 64.  
Guideline #13 concerns how to treat bone disease in CKD patients.  
Paragraph A of this Guideline concerns “Hyperparathyroid (high-turnover) and mixed (high 
turnover with mineralization defect) bone disease”. In this paragraph, we can find information 
on the therapeutic and dietary instructions on the treatment of CKD patients (stages 3 and 4) 
“with intact PTH> 70 pg/ml (stage 3) or >110 pg/ml (stage 4) on more than 2 consecutive 
measurements” and for stage 5 CKD patients “with intact PTH> 300 pg/ml”. 
 
Paragraph C of the Guideline deals with adynamic bone disease in stage 5 CKD patients 
(determined by bone biopsy or intact PTH< 100 pg/ml). 
 
Guideline #14 recommends parathyroidectomy in patients with severe hyperparathyroidism 
(defined as persistent serum levels of intact PTH> 800 pg/ml, associated with hypercalcemia 
and/or hyperphosphatemia that are refractory to medical therapy).  
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Figure 16: Management of CKD patients (stages 3 and 4) regarding the PTH levels of the 
patient 
 
 
 
 
It should be noted that these intact PTH “cut-offs” have been obtained with the Nichols 
Allegro kit – which is no longer available on the market. This point is not specified in the 
guidelines.  
Given the various cross-reaction degrees of the antibodies used in the intact PTH kits and the 
non-(1-84) PTH, this has two serious consequences: 
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- the intact PTH goals described in the  Guidelines are only  applicable sensu stricto to 
the Allegro kit. 
- any change in the PTH determination method can affect the longitudinal follow-up of 
the patients 
We emphasized this point in 2005 65. Indeed, as many other laboratories, we planned to move 
from an IRMA method (DiaSorin) to a chemiluminescent automate (Liaison, DiaSorin) in 
order to have the possibility to perform both PTH and 25-OH vitamin D at the same time on 
the machine.  
Even if the antibodies used in the two methods were the same, this change has had an 
important impact on the results of the CKD patients. We showed that, in 78 hemodialyzed 
patients, we had a mean difference of 68 pg/ml on the Bland-Altman plot, which is far from 
negligible (Figure 17).  
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Figure 17: Comparison of the values obtained in 78 hemodialyzed patients with the 
DiaSorin IRMA and Liaison with the Bland and Altman plot. 
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Moreover, all the results obtained with the Liaison were higher than those that we used to 
have with the IRMA (mean difference of 33.8%). In the study, 22 patients were within the 
150-300 pg/ml range with the DiaSorin IRMA. As mentioned above in the Guidelines, this 
range was supposed to be the target range to avoid secondary hyperparathyroidism or 
adynamic bone disease in the hemodialyzed patients. In this subgroup, the Bland-Altman plot 
showed a mean difference of 37%, and the 90% confidence interval range found by the 
Liaison assay for this population was 204-409 pg/ml, with some of these patients classified as 
suffering from secondary hyperparathyroidism. 
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The discrepancies linked to the different assays used were nicely described one year later by 
Jean-Claude Souberbielle 63. In this multicentric study, he correlated all the kits available on 
the market with the famous 150, 300 and 1000 pg/ml cut-offs determined on Allegro. It was 
striking to see that, with some kits, patients could either be considered as suffering from 
adynamic bone disease or secondary hyperparathyroidism! 
 
Figure 18: Results obtained with different PTH assays for “Allegro” values of 150, 300 and 
1000 ng/L (Souberbielle et al. Kidney Int 2006). The highlighted techniques are the 
“standard” Allegro intact PTH, the N-tact PTH IRMA and the Liaison from DiaSorin and 
the kits that present the highest and the lowest values for each pool.   
 
 
However, when we went back to our population described one year before with the IRMA 
and the Liaison, we saw that what we considered as patients “under control” (between 150 
and 300 pg/ml with the DiaSorin IRMA) were clearly suffering from hyperparathyroidism as 
the values of our kit were roughly the half of the Allegro kit…(Table 2). Moving to Liaison 
reduced this gap, as our values raised by 37%, which allowed us to slightly better classify the 
patients.  
  Determination of PTH in CRF patients 
 
 74
 
Table 2: Classification of 78 patients from the Hemodyalisis Department of our Hospital, 
according to DiaSorin IRMA (the currently used method I the Laboratory), Liaison (the 
new method) and the “equivalent Allegro” calculated according to Souberbielle. 
 
 IRMA  Liaison Equivalent Allegro 
ABD 46 32 24 
Normal 17 23 22 
Hyperparathyroidism 15 23 32 
 
Thus, with the DiaSorin IRMA, any classification of the patients according to the K/DOQI 
guidelines was impossible. Indeed, the prevalence of the patients suffering from adynamic 
bone disease was clearly overestimated, and the number of patients suffering from 
hyperparathyroidism was underestimated. Finally, “normal” patients with the DiaSorin IRMA 
suffered, in fact, from secondary hyperparathyroidism!  
 
Two years later, DiaSorin launched a second version of the Liaison intact PTH. We validated 
this new version according to our quality procedures and published the results of this 
validation 58. For this validation, we compared, in hemodialyzed patients, the results obtained 
with the new version and another chemiluminescent method, Roche Elecsys PTH. We had 
also the data obtained with the former version of the Liaison PTH and the DiaSorin IRMA. 
When we go back to these data, some points are striking: 
- the regression equation between Elecsys (which is probably calibrated against the 
Allegro, as we can see from the already cited paper of Jean-Claude Souberbielle) and 
the DiaSorin IRMA is DiaSorin IRMA=0,5738XElecsys+3,3 (R²=0,9499, p<0,001). 
When we used this equation to evaluate what are the “DiaSorin IRMA equivalents” 
for Elecsys values of 150 and 300 pg/ml, we found data that are closed to those 
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published by Souberbielle for this method (89 and 175 vs. 83 and 160 pg/ml for 
Souberbielle). 
- Souberbielle confirms in his paper the 37% difference that we observed between the 
IRMA and the 1st version of the Liaison PTH. 
- In 2007, when we published the validation of the 2nd version of the Liaison PTH, our 
results showed that the DiaSorin IRMA was still underestimating the Elecsys by 50%. 
However, the 2nd and even the 1st version of the PTH Liaison were much more in 
accordance with the Roche Elecsys PTH. Indeed, the results obtained with the 
regression equations were, for Elecsys values of 150 and 300 pg/ml: 162 and 296 for 
the 1st, and 158 and 288 pg/ml for the 2nd version of the Liaison. This indicates that, 
during a two-year period, DiaSorin modified the calibration of the kits on Liaison in 
order to give values that are closer to the Elecsys (and Allegro). This implies, de facto, 
that the results of our patients changed from 2005 to 2007, with possible clinical 
consequences on the follow-up of the CKD patients. 
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2. The new KDIGO guidelines 
 
Very recently (August 2009), the KDIGO (Kidney Disease Improving Global Outcomes) 
stated, in Chapter 4.2 “Treatment of abnormal PTH levels in CKD–MBD” that “In patients 
with CKD stage 5D, we suggest maintaining iPTH levels in the range of approximately two to 
nine times the upper normal limit for the assay”. As we will see later, the problem of defining 
a “reference range” for PTH is quite difficult and the discrepancies between the different kits 
and the different laboratories will probably remain. 
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C. ANALYTICAL INTERFERENCES IN PTH TESTING. 
 
 
 
 
 
 
 
 
False positive PTH results: an easy strategy to test and detect analytical interferences in 
routine practice 
 
Cavalier E, Carlisi A, Chapelle JP, Delanaye P..  
Clin Chim Acta 2008; 387:150-2 
 
 
An unusual interference in parathormone assay caused by anti-goat IgG: a case report. 
 
Cavalier E, Delanaye P, Carlisi A, Chapelle JP, Collette J.  
Clin Chem Lab Med 2009; 47:118 
 
 
Human anti-mouse antibodies interferences in Elecsys PTH assay after OKT3 treatment 
 
Cavalier E, Carlisi A, Chapelle JP, Orfanos P, Uzan M, Falque V, Delanaye P, Hachicha M.. 
Transplantation 2009; 87:451-2 
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Immuno-assays are largely used throughout the world for the diagnostic or the follow-up of 
many diseases. Clinicians rely on those tests and are not necessarily aware of interferences, 
preanalytical 66 and analytical 67-69 problems that can lead to misdiagnosis or expensive 
complementary explorations 70. Natural antibodies are the major source of heterophile 
antibody interference (HAMA) 71. Many authors have also shown that rheumatoid factors 
(RF), which are autoantibodies mainly of the IgM class binding preferably to IgG antibodies, 
can cause interference in immunoassays 72-74 
As other immunoassays, PTH determination is not free from these interferences, which can 
induce falsely elevated results, leading to misdiagnosis and expensive unnecessary 
explorations. However, in routine practice, these interferences are not always obvious to 
detect. We thus established a validation protocol which could allow us to detect these 
interferences in our routine PTH determinations 75. 
We have reported two cases of HAMA interference: one with the Liaison and one with 
Elecsys. The interference observed with Liaison has been detected in our laboratory by our 
validation protocol and has had no impact. The sample on which we observed an interference 
with Elecsys was sent to us for an expertise. Unfortunately, in this case, the interference has 
led to unnecessary and cost-effective extra investigations. 
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1. False positive PTH results: an easy strategy to test and 
detect analytical interferences in routine practice.  
 
We aimed to evaluate the occurrence of analytical interferences on PTH determination with 
DiaSorin Liaison and to present a protocol for PTH validation, easily applicable in practice 
and which takes these interferences in consideration.   
 
PTH  results have to be interpreted together with serum 25-hydroxyvitamin D (25VTD),  
ionized calcium (Ca++) results and with the estimation of glomerular filtration (eGFR) rate by 
the MDRD equation 76. We considered an elevated PTH (>60 pg/ml, 6.30 pmol/l) result with 
normal 25VTD (>32 ng/ml, 80 nmol/l), normal Ca++ (comprised between 1.15 and 1.30 
mmol/l) and eGFR >60 ml/min/1.73 m² as suspicious. Suspicious samples were treated, 
according to the manufacturer’s instructions, with Heterophile Blocking Tubes (Scantibodies, 
Shantee, CA) to evaluate a possible interference with HAMA. As controls, 118 HAMA-
negative patients were treated. We observed a recovery of 91.7%, a valuable result to consider 
HAMA treatment as acceptable, according to Ellis and Livesey 77. 
Then, RF determination was performed on HAMA negative samples on BNII (Siemens 
Diagnostics, ex-Dade Behring, Marburg, Germany). A sample was considered as RF-positive 
when the RF level detected was > 11 UI/ml. 
 RF-positive samples were then treated with RF-Absorbent® (IBL, Hamburg, Germany), a 
reagent containing anti-human IgG antibodies to precipitate RF as follows: 400 µl of serum 
were added with 50 µl of RF-Absorbent, incubated 1 hour at room temperature and analyzed 
in parallel with the non-treated serum.   
Ten RF-negative samples containing a suspicious level of PTH were treated as controls. 
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A sample presenting a drop in PTH level of 20% (twice the inter-assay of the test) after any 
treatment was considered as significantly influenced.  
We started to apply our validation criteria in May 2007. In the end of June, we had 
determined PTH for 2084 patients. Amongst them, 743 presented an elevated level of PTH 
(36%). We found a plausible reason for this result in 91% of the cases (54% of them were 
renal insufficient, 34% had a suboptimal level of 25VTD and 3% an abnormal calcium level). 
However, there were 63 patients for which the level of PTH could be considered as 
suspicious. After treatment of these sera with HBT tubes to search for HAMA interference, 
we observed a decrease of PTH in 25 of them (mean fall: 29%) and the level of 13 samples 
returned into normal range (Figure 19).  
Amongst the 38 remaining patients with suspicious PTH which did not present HAMA 
interference, 21 were found to be positive for rheumatoid factor. PTH results obtained after 
RF-Absorbent treatment on these 21 samples, as well as RF values, are presented in Table 3. 
We observed a fall of more than 20% in PTH in 9 samples (43%) and the mean decrease in 
PTH levels observed in these samples was 46%. For 6 of them, PTH even returned into the 
normal laboratory ranges. 
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Table 3: Results of PTH obtained in 21 RF-positive samples before and after treatment with 
RF-Absorbent®. In bold, samples in which a decrease of more than 20% has been 
observed.  
 
 
RF (UI/ml) PTH before 
treatment (pg/ml) 
PTH after treatment 
(pg/ml) 
Difference (%) 
20 114 107 -6 
21 80 71 -11 
21 63 59 -6 
35 63 40 -37 
35 63 63 0 
48 79 75 -5 
58 134 104 -22 
59 101 90 -11 
71 62 60 -3 
83 79 67 -15 
95 74 56 -24 
116 114 96 -16 
161 65 50 -23 
360 68 56 -18 
402 186 60 -68 
418 62 44 -29 
438 210 204 -3 
439 139 14 -90 
500 66 35 -47 
503 169 62 -63 
527 63 62 -2 
 
There was no correlation between RF level and the difference in PTH observed after 
treatment. 
In the control population, the mean PTH decrease was 5% and none of the 10 samples tested 
presented a fall of more than 20%.  
 
Immuno-assays are very largely used throughout the world for the diagnostic or the follow-up 
of many diseases. Clinicians rely on those tests and are not necessarily aware of interferences 
that can lead to misdiagnosis or expensive complementary explorations 69, 70. Natural 
antibodies are the major source of heterophile antibody interference 71 and many authors have 
shown rheumatoid factor interference in immunoassays 72-74.  
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PTH determination on Liaison, as well as many other immunoassays, is not free from these 
interferences. In this study, we have shown that the serum of 34 of the 743 patients with an 
elevated PTH level presented in fact interference due to HAMA or RF (interference rate: 
4.5%). Moreover, PTH of 18 of these patients returned into normal range after treatment. 
Nevertheless, one should keep in mind that even if the result observed after treatment was not 
back into the normal range, this does not mean that the patient has a pathologic PTH, as the 
interference hides the “true value”. However, as it is not economically viable to test any 
positive PTH sample with HBT or RF-absorbent, a strategy should be applied to validate 
PTH. 
We have presented a simple three steps protocol, easy to apply in routine with new generation 
of laboratory information systems, which allowed us to screen for suspect PTH results. 
Firstly, we took into consideration 3 parameters, essential for a correct PTH clinical 
interpretation and that should be available at the time of validation:  25 OH-vitamin D, 
calcium levels and an estimation of the renal function. With these criteria, we found a 
plausible explanation for an elevation of PTH levels in 91% of our patients. 
Then, suspect PTH values were confirmed by HBT treatment to remove the possible HAMA 
interference. We found that 40% of the 63 suspect samples were positive for HAMA.   
Amongst the 38 HAMA-negative samples, we performed a rheumatoid factor determination. 
We found it to be positive in 55% of the cases. Finally, these 21 RF-positive samples were 
treated with RF-Absorbent®. 
This strategy, tested on Liaison, could basically be applied to any PTH method. However, it 
should be noticed that RF-Absorbent treatment has to be validated in order to avoid matrix 
effects. Moreover, we can not presume the percentages of interferences that might be 
observed with these other methods. Indeed, lack of standardisation and  complexity of PTH 
determination 63 are closely related elements explaining, at least partially, these assays 
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problems. Once again, one should also keep in mind that the validity of any treatment used to 
overcome interferences should be checked for each PTH determination kit 77.  
In conclusion, by this method, we managed to avoid spuriously elevated PTH results which 
could have cause medical errors as well as unnecessary cost-effective extra-investigations. 
 
2084 PTH 
determinations
743 elevated
PTH (36%)
63 suspicious
PTH (9%) 
?20% in PTH: 
n=25 (40%)
38 suspicious left
21 RF-positive 
?20% in PTH: 
n=9 (43%)
PTH < 60 pg/ml excluded
Easy « clinically explanable » elevated PTH
HBT treatment
RF determination
RF-Absorbent treatment
  
Figure 19: Results of the strategy used in the Laboratory to validate the PTH results 
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2. An unusual interference in PTH assay caused by anti-goat 
IgG: a case report.  
 
We reported the case of a 29 yo woman, working as a nurse, who underwent a blood analysis 
to monitor hypothyroidism. In addition to the “classical” parameters, her physician ordered a 
parathormone (PTH) determination. The result of the PTH was found to be >2000 pg/ml 
(normal range: 12-58 pg/ml) with Liaison. As we just discussed 75 ,we considered this result 
as “spurious” and we treated the sample with HBT (Heterophilic Blocking Tubes, 
Scantibodies, Santee, CA) and RF-Absorbent (IBL, Hamburg, Germany) to remove a possible  
interference due to human anti-animal antibodies (HAAA) and rheumatoid factor (RF), 
respectively. We also determined PTH with Roche Elecsys. We observed that the result 
remained unchanged after HBT treatment whereas PTH dramatically felt at a value of 40 
pg/ml after anti-RF treatment. On Elecsys, the PTH was also normal (24 pg/ml). We thus 
suspected an interference due to RF, but the patient neither suffered from rheumatoid arthritis 
(nor any other autoimmune disease), neither was positive when we tested her for RF (BN2, 
Siemens, Marburg, Germany). To explore the reason for this interference on Liaison we then 
performed a chromatographic separation with a Superdex 200 HR 10/30 column (Amersham 
Biosciences, Piscataway, NJ) and we concluded that there was PTH reactivity in the fraction 
that corresponded to the molecular weight of the IgG’s. This confirmed the results of the RF-
Absorbent treatment, which, indeed, is a treatment of the sample with anti-IgG antibody. 
As the antibodies used for PTH Liaison are polyclonal goat antibodies (whereas Roche 
Elecsys use monoclonal mouse antibodies), we suspected that there was anti-goat IgG present 
in the serum of the patient that could interfere with the assay. To confirm this hypothesis, we 
incubated 400 µl of the patient’s serum with 40 µl of goat serum. In this condition, we 
observed that PTH dropped from >2000 to 41 pg/ml. 
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Human anti-animal antibodies are a known cause of interferences in immunoassays 78. This 
patient had no obvious reason to present anti-goat antibodies (any animal contact, professional 
exposition, celiac disease, drug, vaccination or blood transfusion). She did not eat goat cheese 
nor drink milk. A possible cause could be a pregnancy three years before, even if she was 
primiparous 79. Even if the manufacturers write in the inserts of the kits that this kind of 
interference remains possible, one should be careful when interpreting the results of any 
immunoassay. We must keep in mind the tragic outcomes that can be observed with these 
interferences 80. Indeed, these antibodies can give spurious results, leading to unnecessary 
cost-effective and stressful extra-investigations. 
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3. Human anti-mouse antibodies interferences in Elecsys 
PTH assay after OKT3 treatment  
 
We also reported the case of a 61- year old white man with end stage renal disease secondary 
to an autosomal dominant polycystic kidney disease (ADPKD).  Dialysis therapy was 
commenced in 2003 and he received a renal transplant from a deceased donor in 2004. His 
circulating PTH concentration before transplantation was 287 pg/ml as measured by the 
Roche Elecsys immunoassay analyser, in the target of the K/DOQI recommendations 64. The 
transplanted kidney functioned until 2007 and then failed due to acute cellular rejection.  He 
received standard anti-rejection medication (i.v. steroids and OKT3) but did not respond, lost 
function of his renal graft and returned to hemodialysis in February 2007. Four months later, 
the renal graft was removed because of systemic manifestations of rejection. From March to 
December 2007, plasma PTH concentrations were measured every 3 months again by Roche 
Elecsys. The results showed a rise of PTH after 7 months on hemodialysis, and this was even 
more dramatic after 10 months. No parathyroid mass was identified either by 99Tc-Sestamibi 
or ultrasound scans. An interference in the PTH assay was thus suspected and the sample was 
sent to our Laboratory where  extra-investigations were performed, as described in the 
previous chapter. The treatment of the sample with HBT (Heterophilic Blocking Tubes, 
Scantibodies, Shantee, CA), which removes human anti-animal antibodies (HAAA), resulted 
in an important decrease of PTH, from 3748 to 552 pg/ml. Treatment with anti-rheumatoid 
factor (IBL, Hamburg, Germany) did not result in a significant change in PTH.  PTH was then 
measured by a different second-generation chemiluminescent immunoassay (Liaison) which 
uses polyclonal anti-goat antibodies and showed a result at 605 pg/ml, not altered by inclusion 
of HAAA or RF.  By contrast the suspect Roche Elecys intact PTH assay uses two murine 
monoclonal antibodies. Thus these two assays use antibodies derived from different animal 
species which bind to different epitopes on the PTH molecule. This led us to conclude that 
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there was an analytical interference in the PTH determination by Elecsys, and that this 
interference was due to a human anti-mouse IgM. 
Treatment with OKT3, a murine monoclonal antibody directed against the CD23 of human T-
cell antibodies, is well known to induce the production of human anti-mouse antibodies 81. 
These antibodies can reduce the efficiency of the drug by blocking the interaction with the 
target cells, but can also interfere with the immunoassays that use murine antibodies 82.  Such 
interferences are not always obvious to detect, particularly in the case of hemodialyzed or 
transplanted patients, where high circulating concentrations of PTH can be expected.  
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D. ESTABLISHMENT OF A “REFERENCE RANGE FOR PTH”: 
IMPACT ON THE DIAGNOSIS OF PRIMARY AND SECONDARY 
HYPERPARATHYROIDISM. 
 
 
 
 
 
Analytical validation of the new version of the Liaison N-Tact PTH assay.  
Cavalier E, Delanaye P, Carlisi A, Krzesinski JM, Chapelle JP 
Clin Chem Lab Med 2007; 45:105-7 
 
Defining a “Reference Population”: No Easy Task 
Cavalier E, Delanaye P 
Journal of Bone and Mineral Research, 2009 Sep;24(9):1638 
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The diagnostic of primary and secondary hyperparathyroidism is essentially biological. Thus, 
determination of a strong reference range for PTH is of importance. This has recently been 
emphasized by Eastell et al when they published the new guidelines for the management of 
the asymptomatic primary hyperparathyroidism 83. Indeed, they insisted on the necessity to 
determine optimal reference ranges for PTH – which are lacking for the moment. On the other 
hand, ISO 15189 guidelines ask laboratories to check periodically the reference range 
proposed by the manufacturers. However, these guidelines do not explain how to check for 
these reference ranges. Generally, the best way to establish them is to select a determined 
number of samples from a healthy population and to assay the parameter concerned. Then, if 
the distribution is “normal” (this can be evaluated by statistical means, ie with the 
Kolmogorov-Smirnov test) the mean +/- 2 standard deviations represent 95% of the 
population. So if we take these values for the upper and lower limits, it means that 2.5% of 
healthy people will be classified as having “too high” and “too low” values for the parameter 
studied. For some parameters, where a “cut-off” is needed, the 5% can be one-sided, right or 
left. 
If the population is not statistically “normal”, there are different means, as logarithmic 
transformation or the use of non-parametric tests, to define the reference ranges. 
Nevertheless, one question remains: how do we define a “normal population”? 
Generally, blood donors were used to be considered as a “normal healthy population” and a 
lot of reference values have been established in this population. However, on one hand, most 
of laboratories do not have access to these patients and on the other hand, it may be subjective 
to think that these people are always “healthy” for every parameter tested: these patients are 
generally young, declare that they consider their selves as “healthy” and have a 
“conventional” sexual behaviour. This does not mean that they suffer from a deficiency that 
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can not modify some of their parameters, nor that their diet or alcohol consumption is 
“normal”…. 
From our point of view, we think that the best way to define a reference population is to select 
the samples on which the parameter will be assayed with the help of pre-determined 
biological (or clinical) criteria 48. So, if we apply this concept to the determination of the 
reference ranges for PTH, we should test samples that do not present obvious biological signs 
of primary or secondary hyperparathyroidism. These samples should also be free from any 
obvious interference, like rheumatoid factor. 
We thus generated fasting reference intervals for the Liaison PTH and Roche Elecsys PTH 
assays using 60 patients (11 male, 49 female) aged 23–85 years 58. 
Our criteria for inclusion were: 
- 25-OH vitamin D levels >50 nmol/L,  
- glomerular filtration rate evaluated by the MDRD formula >60 mL/min/1.73 m² 
- negative rheumatoid factor (RF)  
- total calcium level within the laboratory reference range (2.20-2.60 mmol/L).  
- total phosphorus level within the laboratory reference range (0.74-1.51 mmol/L).  
 
The reference interval was determined to be 12–54 pg/mL for the DiaSorin Liaison and 14–52 
pg/mL for the Roche Elecsys assays. We found no age- or gender related differences. 
These upper values of our established reference interval were much lower than the ones 
proposed by the Manufacturers (-19 pg/mL for DiaSorin, -13 pg/mL for Roche). Indeed, these 
societies did not select the patients as we did, including patients that could have presented 
secondary or primary hyperparathyroidism in their reference population.  
The impact of lowering the reference range was clinically important: indeed, in 2008, we have 
performed 15243 PTH determinations with the DiaSorin Liaison. Among them, 2732 (17.9%) 
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patients were comprised between 54 (our calculated upper value) and 73 pg/mL (the upper 
value proposed by DiaSorin). We found that the majority of these “elevated” PTH were due to 
vitamin D insufficiency that had led to secondary hyperparathyroidism. 
Once again, as the diagnostic of primary and secondary hyperparathyroidism is mainly 
biological, the patients with a mildly elevated PTH will be missed by using the 
manufacturers’ reference range. 
Therapeutic actions (ie, supplementation with native vitamin D) will thus be delayed. 
 
On the other hand, as we already mentioned, the KDIGO recently published new guidelines, 
stating that “in patients with CKD stage 5D, we suggest maintaining iPTH levels in the range 
of approximately two to nine times the upper normal limit of the assay”. 
We already explained the problems encountered when Nephrologists wanted to follow the 
K/DOQI guidelines and transposed the “150-300 pg/mL” to the other techniques. The good 
point with the KDIGO guidelines is that they do not deal anymore with absolute values, but 
rather refer to the “normal range” of the assay used in the laboratory. Unfortunately, we are 
facing another problem: indeed, most of the labs use, as reference range, the data provided by 
the manufacturers in the inserts of the kits whereas all manufacturers implicitly request in 
these folders that the laboratories have to establish their own reference range… 
If we multiply by 2 and 9 the upper reference range published by DiaSorin for the Liaison (73 
pg/mL), we obtain a range of 143 to 657 pg/mL; for the Elecsys (65 pg/mL), it will be 130 – 
585 pg/mL. However, if we use the PTH reference range established with our criterion (cf 
supra), the patients should be maintained between 108 and 486 pg/mL if they are followed 
with Liaison and 104 – 468 pg/mL if they are followed with Elecsys. These discrepancies are 
far from negligible. 
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A. NON-(1-84) PTH, PTH RESISTANCE AND CKD MINERAL BONE 
DISORDERS. 
 
Evaluation of different bone markers in hemodialyzed patients. 
 
Cavalier E, Delanaye P, Collette J, Krzesinski JM, Chapelle JP. 
Clin Chim Acta. 2006 Sep;371(1-2):107-11 
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1. The (non-1-84) PTH. 
As we already mentioned, PTH circulates in the blood in its “complete” (1-84) form, next to 
different amino- or carboxyl-truncated fragments. These fragments can come from the hepatic 
degradation of the peptide or can be secreted by the parathyroid gland itself. We already saw 
that these fragments, and particularly the big C-terminal fragments, interfere with the PTH 
assays. This was true for the 1st generation PTH RIA kits, but the 2nd generation kits presented 
also an interference with the “non-(1-84) PTH”.   
This “non-(1-84) PTH” is composed of a family of fragments, the longest and the shortest 
fragment starting at position 4 and at position 15, respectively. The major component of the 
non-(1-84) PTH is a peptide starting at position 7. This is the reason why the non-(1-84)PTH 
is generally called PTH (7-84) 84.   
(1-84) PTH
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(7-84) PTH: the most important
fragment of the non-(1-84) PTH
NH2
 
(15-84) PTH: the shortest fragment 
of the non-(1-84) PTH
NH2
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(4-84) PTH: the longuest fragment 
of the non-(1-84) PTH
NH2
 
 
 
Non-(1-84) PTH represents about 20% of intact PTH in normal individuals, but up to 50% in 
patients with terminal CRF. The fragments that compose the non-(1-84) PTH are cleared by 
the kidneys and accumulate in CKD patients, proportionally to the importance of their renal 
disease. They are also secreted by the parathyroid glands and generated when PTH is 
metabolized. In fact, two forms of secretory granules have been identified in the parathyroid 
cells 85. The first one contains, of course, the (1-84) PTH in its complete form, but the second 
type also contains different cleavage enzymes (cathepsins B and H) 86 and (1-84) PTH. Low 
extracellular calcium promotes the release of PTH (1-84) in the circulation. However, when 
the CaSR is activated by circulating elevated Ca++ levels, it causes the release of intracellular 
Ca in the parathyroid cells, which in turn inhibits the secretion of PTH (1-84) in the 
circulation. This inhibition is accompanied by an enhanced proteolysis of the NH2-terminal 
part of the PTH peptide by the cathepsins. The result of this proteolysis thus becomes the non-
(1-84) PTH. 
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2. Activity of the non-(1-84) PTH: the PTH resistance   
 
Traditionally, the non-(1-84) fragments have been supposed to be inactive, as they lacked the 
amino-terminal form of the (1-84) PTH.  
However the dynamic balance between the secretion of these fragments and of (1-84) PTH, 
controlled by free calcium, raises some questions 87. Moreover, as the peripheral metabolism 
of PTH is unaffected by changes in calcium 88, one could think that the secreted ratio between 
the different PTH moieties is of clinical importance.  
As already said in the previous chapter, PTH1R signaling requires the first four amino-acids 
of the peptide. However, it has been shown that the non-(1-84) PTH down-regulated the 
biological activity of 1-84 PTH and caused internalization of the PTH1R receptors, without 
activating them 89. This is of importance in uremic patients, where high levels of these 
fragments can be found, and could probably explain part of the tissue “resistance” to PTH that 
characterizes chronic renal failure (this “resistance” can be defined as the difference in 
biological response of target organs to a same excessive concentration of PTH). 
Indeed, if PTH resistance is not completely understood, two theories have emerged to explain 
it. The first one, developed by Slatopolsky 90, is based on the fact that PTH (7-84) antagonizes 
the calcemic actions when given to a molar ratio 1:1 with PTH (1-84) in 
parathyroidectomized rats. These authors think that PTH (7-84) could thus act as a 
competitive inhibitor of PTH (1-84) for PTH1R.  
There are some limitations to this theory: indeed, as pointed by Friedman 85, downregulation 
of PTH1R is generally observed in CRF 91-93, independently of any resistance. Secondly, it 
was proven in rats, not in humans - and these rats had not renal insufficiency.   
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At that point of the discussion, we should introduce the Na+/K+/Exchanger Regulatory Factor 
1 (NHERF1) and its role on PTH1R regulation. NHERF1 is a cytoplasmic protein that 
regulates trafficking of several G protein-coupled receptors – including PTH1R. NHERF1 
promotes the membrane retention of PTH1R, stabilizes it at the cell membrane and increases 
the fraction of receptor at the cell surface 94. NHERF1 thus inhibits endocytosis without 
affecting PTH1R recycling and such an effect protects against PTH resistance or PTH1R 
downregulation.        
In kidneys, PTH1R is expressed in proximal tubules, cortical ascending limbs and distal 
convoluted tubules 95. Distal tubular cells lack sufficient amounts of NHERF1 and thus, in 
these cells, the PTH1R receptors are more prone to be downregulated by PTH (7-84) 85. This 
downregulation will be associated in these cells with a reduction in PTH mediated calcium 
transport.  
In the other cells that contain both PTH1R and sufficient amounts of NHERF1 (proximal 
tubules and cortical ascending limbs cells), there is no internalization of the PTH1R after 
exposure to PTH (7-84). As these cells contribute to the PTH-regulated phosphorus transport, 
the inhibitory effect of PTH on phosphorus transport is not affected.  
The consequences of the effects of PTH (7-84) would thus be a resistance to the 
hypercalcemic effect of PTH, but a preservation of its phosphaturic effect. 
 
The second theory is based on the studies published by Divieti and Bringhurst 96-98 which 
introduce evidence for a new PTH receptor, which who would interact with the carboxyl-
terminal part of the peptide (C-PTHR). Indeed, PTH (7-34) analogues do not lower calcium in 
hypercalcemic mice 99, suggesting that the end of the peptide is important for the inhibitory 
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action. On the other hand, amino-truncated fragments stimulate bone alkaline phosphatase 
(bAP) activity and induce the expression of mRNAs for bAP and calcitonin 100, 101. 
This hypothesis is elegant, but the C-PTHR receptor has still to be found. We have an indirect 
proof of its existence as we know, from experiments, that PTH (19-84) can bind osteoblastic 
and osteolytic cell lines from mice KO for the PTH1R 96. Moreover, the hypothetic role 
played by this receptor in the PTH resistance has still to be clarified.   
Further work is thus needed to completely understand the PTH resistance in uremia. 
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3. CKD Mineral Bone Disorders 
 
CKD Mineral Bone Disorders represents the various forms of skeletal disease of the CKD 
patients, and may appear as a high bone turnover due to hyperparathyroidism, a mixed form 
(hyperparathyroidism with defect of mineralization) or a low bone turnover (adynamic bone). 
In all cases, the patients suffering from this disease are at high risk of fractures, vascular and 
extra-vascular calcifications.  
The gold standard for the diagnosis of the CKD Mineral Bone Disorders is the 
histomorphometric and the histochemical examination of a bone biopsy specimen obtained 
after double labelling with tetracycline 102. However, this invasive procedure is only 
performed in specialized centres and is not easily accepted by the patients. Bone mineral 
densitometry 103 has been evaluated in the diagnosis and/or monitoring of renal bone disease, 
but data are clearly insufficient. Routinely, nephrologists rely on measurements of different 
serum biochemical markers to diagnose which type of renal bone disease is present, initiate 
appropriate treatment and make the follow-up of the patients. The most frequently used is 
PTH (in conjunction with calcium and phosphorus), but PTH measurement has clear 
limitations, especially in CKD patients. 
In 2001, however, the scientific community paid a particular attention to a paper published by 
Monier-Faugere et al in Kidney International 104. Indeed, these authors reported that all their 
patients with low bone turnover (LBT) presented a 
PTHnon
PTH
)841(
)841(
−−
−  ratio <1.  
The 
PTHnon
PTH
)841(
)841(
−−
− ratio was thus presented by these authors as a new tool for the 
diagnosis of LBT. This study had been performed in 51 hemodialyzed patients vs. bone 
biopsy. The patients enrolled had not received active vitamin D or any other drug that could 
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have had an effect on bone metabolism for 6 months. The mean vintage time on dialysis of 
these young (47±3 y.) patients was 25.6±3 months. 
In the literature, an important scientific debate immediately followed this publication. 
Indeed, one year later, Coen et al 105 did not find similar data. For these authors, there was no 
correlation between the ratio and bone alkaline phosphatase (bAP), bone formation rate or 
osteoblast surface (which are histomorphic and histodynamic measurements). Coen at al 
based their results on a study involving 35 patients against bone biopsy. Among these 
patients, 9 (26%) suffered from LBT and the 
PTHnon
PTH
)841(
)841(
−−
− ratio observed in these 
patients was not different from that in the other histological groups. One should notice that 
Coen’s population was a little older (57±12 y.) and had spent longer times on hemodialysis 
(61±66 months) than the one of Monier-Faugère. The majority of Coen’s patients had 
discontinued calcitriol therapy between 1 and 4 months before biopsy (vs. over >6 months for 
Monier-Faugère). However, the mean 25-OH vitamin D levels of these patients was quite 
elevated, at 25±13 ng/mL (data not presented by Monier-Faugère).  
One year later, in a study involving 33 paediatric patients (13±4 yo) treated with continuous 
cycling peritoneal dialysis for 13±9 months and who underwent bone biopsy, Salusky et al 106 
showed that PTH concentrations (2nd or 3rd generation) were a better predictor factor than the  
PTHnon
PTH
)841(
)841(
−−
−  ratio. In these patients, calcitriol therapy had been held for 4 weeks before 
the bone biopsy. The 25-OH vitamin D data were not provided. Ten over 33 (30%) of the 
patients were considered to have normal/reduced bone turnover (the sample size of patients 
with adynamic bone was very small). The bAP values of the patients suffering from 
secondary hyperparathyroidism was significantly higher than those of the patients in the 
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normal/low bone turnover group (469 vs. 264 IU/L, p<0.02), but the 
PTHnon
PTH
)841(
)841(
−−
−  ratio 
did not differ between the two groups, in contrast to the study of Monier-Faugère. 
The same year, Reichel et al, in a study involving 141 patients, but no bone biopsy 57 
indirectly showed that the 
PTHnon
PTH
)841(
)841(
−−
−  ratio could not be a predictor of LBT, because 
in most of the studies, the proportion of patients that suffer from this disease is around 30% 
and in his population, only 4% of the patients presented a 
PTHnon
PTH
)841(
)841(
−−
− ratio <1. The 
patients enrolled in Reichel’s study were monthly treated with 20 000 IU vitamin D3 (mean 
serum 25-OH vitamin D levels: 50±27 ng/mL) and most of them were under calcitriol or 
alfacalcidol therapy. 
When we look at these different and conflicting results, we must admit that it is not obvious to 
make one’s opinion on the interest of using the 
PTHnon
PTH
)841(
)841(
−−
−  ratio in routine practice. 
However, an important point is the methodology used in these studies – and particularly the 
time elapsed between the biopsy and the last active vitamin D (or calcimimetics) injection. 
Indeed, we are dealing here with some patients presenting a low or a high bone turnover on 
the bone biopsy. In patients having stopped recently (say one month) an active vitamin D 
treatment, bone biopsy may reflect a low turnover (as it can take many months to achieve a 
remodelling cycle in this case) whereas PTH may be high reflecting the current status of the 
calcium balance. In those presenting a high bone turnover, the PTH or bone turnover markers 
could rapidly decrease after the injection of calcitriol whereas the biopsies will still present 
signs of high bone turnover.  When we analyse the different studies, we must admit that it was 
Monier-Faugère’s protocol that could better explain the correlation of the markers and the 
results of the biopsy, since the patients enrolled had not received active vitamin D or any 
other drug that could have had an effect on bone metabolism since 6 months. 
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In 2005, we performed a transversal study in 73 hemodialyzed patients. The aim of this study 
was to determine PTH with the 2nd and 3rd PTH generation kits and to estimate the 
PTHnon
PTH
)841(
)841(
−−
−  ratio in our patients.  
The results of the laboratory tests observed in our population are presented in Table 4. 
Table 4: Results of the Laboratory tests performed in 73 hemodialyzed patients. 
Analyte Normal range Mean ± SD Median Range 
Intact PTH Scantibodies (pg/ml) 16-66 244±247 185 5-1237 
bAP (ng/ml) 3-23 21.5±42.5 11.2 5.2-355 
CTXS (pg/ml) <35-680 1913±1322 1624 131-6000 
P1NP (ng/ml) 20-76 596±1340 287 45-11380 
TRAP5b (U/l) 1.4-4.7 4.1±1.9 3.6 1.2-9.5 
Whole PTH (pg/ml) 5-39 148±164 89 4-820 
Non (1-84) PTH (pg/ml)  96±88 83 1-444 
PTHnon
PTH
)841(
)841(
−−
− (%)  1.5±0.7 1.5 0.6-4.0 
PTH Liaison version 1 (pg/ml) 7-82 262±231 217 5-1287 
Ca++ (mmol/l) 1.15-1.30 1.10±0.09 1.09 0.91-1.36 
Serum calcium (mmol/l) 2.15-2.60 2.35±0.14 2.36 2.02-2.74 
Serum phosphate (mg/l) 23-47 52±13 50 23-87 
Serum creatinine (mg/l) 3.8-12.1 89±30 88 25-145 
25(OH)D (ng/ml) > 32 17 ± 8 16 7 – 54 
1,25(OH)2 D (pg/ml) 19-79 5.6 ± 6.2 2.95 <2.1 - 42.2
 
Our results, published in 2006 107, showed that there was a strong correlation between bone 
markers concentrations, particularly between bAP and P1NP (r=0.953).  
The presumed non-(1–84) PTH represented 41.7% of the “intact PTH” in our patients group. 
Intact, whole and non-(1-84) PTH moieties correlated very well together, as well as with the 
other bone markers.  
The 
PTHnon
PTH
)841(
)841(
−−
−  ratio correlated positively with whole PTH and TRAP 5b and 
negatively with total calcium. No correlation was found between this ratio and the usual bone 
markers.  
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There was no correlation between 25VTD and the other analytes. 
We then separated our population into three groups according to the intact PTH levels 
observed with our routine method (group 1: <100pg/ml; group 2: ≥100 to <300pg/ml and 
group 3: ≥300pg/ml). 
Bone formation markers were significantly (p<0.01) higher in group 3 than in the other 
groups.  
Bone resorption markers were significantly lower (p<0.05) in group 1 than in group 2, and 
also lower (p<0.01) in group 2 than in group 3. 
The 
PTHnon
PTH
)841(
)841(
−−
−  ratio was significantly (p<0.05) lower in group 2 than in the two 
other groups, demonstrating similar levels. 
 
Table 5: Comparison of biomarkers (mean and 95% confidence interval) in subgroups of 
patients separated according to their Liaison® iPTH levels (pg/ml) 
 
Biomarker Group 1: iPTH 
<100 pg/ml 
(n=21) 
Group 2: 100 ≤ 
iPTH < 300  
pg/ml (n=27) 
Group 3: PTH≥300 
pg/ml (n=25) 
bAP (ng/ml) 10 (7-12) 11 (9-14) 14 (10-25) a 
CTXS (pg/ml) 1114 (676-1457) b 1709 (933-2150) c 2338 (1587-2752) 
P1NP (ng/ml) 247 (175-417) 280 (164-568) 419 (233-805) 
TRAP5b (U/l) 3.2 (2.7-4.3) 3.5 (2.3-4.1) 4.3 (3.5-5.4) a 
PTHnon
PTH
)841(
)841(
−−
− (%) 1.63 (1.04-1.99) 1.13 (1.31-2.2) d 1.73 (1.31-2.2) 
25VTD (ng/l) 16 (11-22) 16 (13-19) 16 (12-19) 
Homocystein (µmol/l) 27 (20-49) 37 (25-43) 30 (25-36) 
 
a Analyte from group 3 significantly higher (p<0.01) than in group 1 or group 2. 
b Analyte significantly lower (p<0.05) in group 1 than in group 2. 
c Analyte significantly lower (p<0.01) in group 2 than in group 3. 
d Result significantly lower (p<0.05) in group 2 than in the two others groups 
 
In this non-native vitamin D supplemented population, 95% of the patients had a suboptimal 
level of 25VTD (<32 ng/ml). Twenty-four patients (36%) had even severe vitamin D 
insufficiency (arbitrarily defined as 25(OH)-vitamin D levels ≤13ng/ml). For all the studied 
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biological markers, there was no difference between this group and the group of the patients 
with vitamin D levels >14ng/ml. The only exception was for homocystein, which showed 
significantly higher concentrations in the very low 25VTD group (41 vs. 28μmol/l, p<0.05). 
In our patients, the mean 
PTHnon
PTH
)841(
)841(
−−
− ratio was 1.5±0.7%. Twenty percent of them 
presented a 
PTHnon
PTH
)841(
)841(
−−
− ratio <1.  
We did not find any differences in the biomarkers studied between the low ratio group and the 
other patients, excepted that they were significantly younger (58 years vs. 74, p<0.02). They 
also presented higher homocystein levels (48 vs.27μmol/l, p<0.02), not influenced by folate 
intake or folate level. This might be interesting as homocystein is well known to be associated 
with hip fractures and osteoporosis in healthy elderly people 108-110.  
However, when we separated the population in three groups of similar size according to their 
intact PTH levels, we found that the patients in the lowest intact PTH group presented 
significantly lower levels of bone markers. It was in the group of patients considered as “in 
normal ranges” by the K/DOQI guidelines that we found a significantly lower 
PTHnon
PTH
)841(
)841(
−−
− ratio.  
The major limit in our study was the lack of bone biopsy, only performed in very specialized 
centres. Nevertheless, in our non vitamin D3 supplemented population, our data showed a 
weak, but positive correlation between homocystein and 25VTD in the subgroup of patients 
with severe vitamin D deficiency. This correlation could be accidental, as this population is 
more at high cardiovascular risk, but it needs to be tested on larger populations.  
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4. bAP: the new marker of choice? 
The debate is still ongoing to see if the 
PTHnon
PTH
)841(
)841(
−−
− ratio is interesting in clinical 
practice or not. Our results are not really in favour of this ratio. However, we paid much more 
attention to the Bone alkaline Phosphatase for the follow-up of the hemodialyzed patients. 
Indeed, Bervoets et al. 111 found that low levels of bAP (≤10μg/l) was a good index for the 
presence of adynamic bone disease (ABD) in end stage renal failure patients not yet on 
dialysis. None of these patients were administered vitamin D. They compared the biochemical 
results with bone biopsy and found that bAP was a useful diagnostic marker to differentiate 
between ABD/normal bone. More recently, Ueda et al. 112 showed that bAP was a clinically 
useful bone formation marker for predicting reduction of bone mineral density in 
hemodialyzed patients and in diabetic hemodialysis patients with low PTH.  
In our population, 62% of the patients presented bAP levels >10μg/l, and the patients 
belonging to this group were younger, had higher levels of P1NP and CTXS (2.0 X higher), 
TRAP (1.5 X), but the intact PTH concentration, the 
PTHnon
PTH
)841(
)841(
−−
− ratio and 
homocystein levels did not differ between the two groups.  
The strict correlation between bAP and P1NP is interesting and means that both markers 
observe a closely related phenomenon. Ueda et al. 113 have already shown the usefulness of 
P1NP as a marker of osteoblast function in hemodialyzed patients and its usefulness for 
predicting radius bone loss. We think for our part that P1NP, a specific indicator of type 1 
collagen deposition and thus a true bone formation marker might be a new marker of interest. 
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To summarize, for us, bAP among different markers seems to offer the best clinical and 
analytical profile for the diagnosis of bone disease. Indeed, this bone mineralization marker is 
eliminated by the liver – and thus not influenced by the renal insufficiency -, is much more 
stable than PTH and presents very interesting analytical properties. Unfortunately, we lack 
guidelines for the follow-up of the patients with bAP. These guidelines could be established, 
but we need to compare bAP results vs. bone biopsy in a large and well clinically documented 
population.  
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B. THE AMINO-PTH AND THE PARATHYROID CARCINOMA 
 
 
 
 
The ratio of PTH as measured by third and second generation assays as a marker for 
parathyroid carcinoma 
 
Etienne Cavalier, Daniela Betea, Pamela Nicoleta Pruteanu-Apetrii, Pierre Delanaye, Adrian 
F. Daly, Phil Stubbs, Arthur R. Bradwell, Jean-Paul Chapelle, Albert Beckers, submitted 
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Parathyroid carcinoma (PCa) is a rare disease, with a prevalence of 0.005% of all cancers 114. 
Fewer than 400 cases of parathyroid carcinoma were reported in the literature before 1993 115 
and in the US National Cancer Database, only 286 cases have been described over 10 years 
116.  PCa accounts for less than 1% of sporadic primary hyperparathyroidisim (PHP) and is 
associated with more severe clinical features than parathyroid adenomas 117. The 
consequences of the severe hypercalcemia linked to unchecked and recurrent PTH 
hypersecretion are the main cause of morbidity and death in patients with PCa. 
Differentiating a rare PCa from a parathyroid adenoma is often challenging, particularly as the 
histopathology of parathyroid tumors can be equivocal 118.  Indeed, the diagnosis of PCa is 
often made definitively only when recurrence or metastasis occurs.  Surgery remains the only 
curative treatment for PCa.  As better outcomes are associated with complete resection of the 
tumor at the time of initial surgery 119, it is important to make a correct diagnosis at the time 
of first occurrence.  Hence, a biological marker that could help to reliably distinguish PCa 
from parathyroid adenoma would be useful. 
As already mentioned, Parathyroid hormone (PTH) circulates in the blood in different forms 
that include full length PTH 1-84, amino truncated PTH fragments of which PTH 7-84 is the 
most abundant, and an N-terminal form of PTH, “amino-PTH”, which may be phosphorylated 
on the serine at position 17 30.  Under physiological conditions, PTH 7-84 represents 15-30 % 
and amino-PTH <10% of total circulating PTH 30. Since 1987 clinical laboratories have 
routinely performed determinations of “intact” PTH using various methods. Second-
generation PTH assays use a capture antibody directed against the (39–84) portion of the PTH 
molecule and a second antibody that recognizes the (13–24) portion of the peptide.  The term 
“intact” is misleading as these PTH assays recognize not only PTH 1-84, but also cross-react 
to varying degrees (50-100%) with a PTH molecule that co-elutes with a synthetic 7–84 PTH 
fragment in HPLC 25.  As PTH 7-84 accumulates in patients suffering from chronic renal 
  Amino-PTH and parathyroid carcinoma 
 122
failure (CRF) this explains in part the overestimation of the secondary hyperparathyroidism in 
CRF cases 23, 24.  A new generation (“third generation”) of PTH assays appeared in 1999. The 
initial third-generation PTH assay used an anti-COOH-terminal antibody like the second-
generation assays, but employed an anti-N-terminal antibody directed against the first four 
amino-acids of PTH 26. These newer assays, therefore, do not measure PTH 7-84 fragment, 
Amino-PTH cross-reacts with third generation PTH kit antibodies but not with antibodies 
used in most second generation assays. The Roche Elecsys assay is an exception and uses an 
antibody that also recognizes amino-PTH 20. 
In healthy individuals, therefore, if the amount of PTH obtained with a third generation assay 
is divided by the amount of PTH obtained with a second generation assay, this 
onndgenerati
onrdgenerati
2
3  PTH ratio (or 
PTHPTH
PTHoAPTH
−−+−−
−+−−
)847()841(
min)841(  ratio) will not be greater than 
1. Indeed, PTH 7-84 physiologically represents a larger proportion of the circulating PTH 
than does amino-PTH.   Recently, it has been shown that the amino-PTH is overproduced in 
PCa 27, 28 and in some rare cases of severe primary hyperparathyroidism 29. In such patients 
the 
onndgenerati
onrdgenerati
2
3  PTH ratio may be inverted (> 1) as compared with normal individuals.  
To date, limited patient series support the hypothesis that the 
onndgenerati
onrdgenerati
2
3 PTH ratio may 
have clinical utility as a marker to discriminate PCa from most cases of benign PHP 27.  
The aim of this study was to undertake an assessment of the 
onndgenerati
onrdgenerati
2
3 PTH ratio in a 
large population of 23 patients suffering from advanced PCa that were referred for assessment 
for an experimental cancer immunotherapy treatment 120. 
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Methods 
Patients 
Twenty three patients from Europe, the United States and Australia were suffering from 
advanced PCa. The clinical characteristics of these patients are described in Table 6. All had 
previously undergone surgery and had been admitted to local hospitals for later administration 
of an investigational treatment to induce an immunologic (anti-PTH antibody) response to 
their tumors after repeated injections of modified PTH fragments 120, 121.  All patients 
underwent assessments of PTH levels before immunological treatment using second and third 
generation assays to derive the 
onndgenerati
onrdgenerati
2
3  PTH ratio. 
As a first comparator group we evaluated the 
onndgenerati
onrdgenerati
2
3  PTH ratio in a population of 73 
chronic renal failure patients undergoing hemodialysis at the Dialysis Unit of the CHU de 
Liège 107. The characteristics of these patients are summarized in Table 7. We also evaluated 
the 
onndgenerati
onrdgenerati
2
3  PTH ratio in a population of 60 renal transplanted patients (Table 8) and 
finally in 82 consecutive healthy elderly patients (mean age 62.0±8.0 years; 53% female), 
who voluntary underwent blood sampling to screen for renal insufficiency. 
 
 
PTH assays 
PTH was determined with the Duo PTH immuno-radiometric kit from Scantibodies 
Laboratory (Santee, CA). This kit includes two different assays: 1) a second generation PTH 
assay that recognizes the PTH 1-84 and the non-PTH 1-84 components, but not the amino-
PTH; and 2) a third generation assay that exclusively recognizes (1-84)-PTH and the amino-
PTH. In our hands, the coefficients of variation obtained with these two assays are <10%. 
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Statistics. 
Statistical analysis was carried out by the Medcalc software (Mariakerke, Belgium). The 
differences between groups were calculated by the Student’s t-test, a p-value <0.05 indicating 
a significant difference. 
 
Results 
The results of the second generation and third generation PTH assays and the 
onndgenerati
onrdgenerati
2
3 ratios are summarized in Table 9. The mean 
onndgenerati
onrdgenerati
2
3 ratio was 
0.58±0.10 in the 73 dialysis patients, 0.54±0.10 in the renal transplant group and 0.54±0.12 in 
the elderly healthy patients. All 207 of these patients presented a PTH 
onndgenerati
onrdgenerati
2
3 ratio of 
<1.  
In contrast to the control populations, we observed an inverted 
onndgenerati
onrdgenerati
2
3  PTH ratio (>1) 
in 20 PCa patients, whereas only 3 patients had a “normal” ratio <1. The mean 
onndgenerati
onrdgenerati
2
3  PTH ratio was statistically significantly higher in the 20 patients presenting 
an inverted ratio (mean: 1.50) as compared to those with a ratio <1 (mean: 0.75; p<0.0001). 
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Discussion 
PTH circulates as a mixture of PTH 1-84 itself and different amino-truncated fragments. 
These fragments are not only products of degradation of PTH 1-84 but are also secreted by 
the parathyroid gland itself. 
 With the advent of the third generation PTH assays, a new circulating form of PTH, amino-
PTH, was discovered. It is still unknown whether this amino-PTH is biologically active or 
not, but has previously been shown to be overproduced in PCa 27, 28 and rarely in cases of 
severe primary hyperparathyroidism 29.  This leads to an inversion of the 
onndgenerati
onrdgenerati
2
3 PTH 
ratio, which is normally <1 in healthy and non PCa populations.  In the current study we 
demonstrate that an inverted 
onndgenerati
onrdgenerati
2
3 PTH ratio was seen in nearly 87% of PCa 
patients, as compared to 0% of a series of three relevant control populations. 
The current study of the 
onndgenerati
onrdgenerati
2
3  PTH ratio as a marker for PCa is the largest to 
address this important question and is itself one of the largest series of PCa patients reported 
to date.  Previous work has suggested the potential utility of this PTH ratio in differentiating 
PCa from the more common benign parathyroid adenoma.  Caron et al observed an inverted 
onndgenerati
onrdgenerati
2
3 PTH ratio (>1) in a patient with PCa 27, but in only 1/30 osteoporotic PHP 
patients with PHP and in 0/294 osteoporotic patients without PHP.  In the PHP patient, the 
inverted ratio remained after surgery (1.54) and the patient exhibited marginal hypercalcemia 
over the course of 3 years follow-up.  Blachowicz reported similar results with 0/32 patients 
with PHP exhibiting an inverted 
onndgenerati
onrdgenerati
2
3 PTH ratio 122.  In one of the largest study to 
date, Rubin et al reported that of eight patients with PCa studied within a larger cinacalcet 
study, four (50%) presented a high ratio 28. This study also showed that when cinacalcet 
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lowered PTH, the inverted ratio remained unchanged. This is not the case when a cure is 
achieved by resection of the tumor, when the ratio is reported to return to normal 29.  
In our study we found the 
onndgenerati
onrdgenerati
2
3 PTH ratio to be systematically <1 among a group 
that included 73 hemodialysis patients, 60 renal transplant patients and 82 healthy elderly 
patients.  Assessing the various published data as a whole, the prevalence of an inverted 
onndgenerati
onrdgenerati
2
3 PTH ratio is very low in PHP patients (1.6%; 1/61) and non-PHP controls 
(0%; 0/530).  In stark contrast, the occurrence of an inverted 
onndgenerati
onrdgenerati
2
3 PTH ratio in the 
PCa population is very high at 78.1% or 25/32 PCa patients reported in our study and by 
others.  We observed three PCa patients with no PTH ratio inversion, whereas Rubin and 
colleagues reported four individuals.  Hence, an inverted 
onndgenerati
onrdgenerati
2
3  PTH ratio has a 
sensitivity of 75.8% and a specificity of 98.4% amongst PHP patients as a tumor marker for 
PCa. 
Our results have been observed in patients suffering from advanced PCa.  It would be 
clinically useful to evaluate the PTH ratio in a population of PCa patients presenting with a 
less advanced stage of malignancy.  A useful clinical application would be the ability to 
identify patients with PCa at an early stage, when the difficulty in distinguishing these 
challenging cases from benign parathyroid adenoma patients is most pronounced.  Also, it is 
clear that a prospective longitudinal study is necessary to capture the PTH ratio in a large 
group of PHP patients before they undergo surgery, and to follow up the entire cohort to 
determine whether those with a persistently inverted PTH ratio or those that later develop an 
inverted ratio are at a greater risk of evolving into cases of PCa.  
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The diagnosis of PCa remains very difficult. Our results, based on one of the largest reported 
cohorts of PCa patients, shows that an inverted 
onndgenerati
onrdgenerati
2
3  PTH ratio may indeed have 
clinical utility as a future tumor marker for PCa, as suggested in smaller series.  Future 
investigations will be needed to assess if the dual determination of PTH with 2nd and 3rd 
generation assays could be proposed in treated patients suspected of having PCa or as a pre-
operative screening test to detect patients in whom an elevated suspicion for PCa exists.  
Alternatively, the 
onndgenerati
onrdgenerati
2
3 PTH ratio could also be used as a new tool in the follow-up 
of the operated patients.  As the ratio returns to normal when the patient is cured, a non-
inverted ratio after surgery, or a ratio that returns to >1 during follow-up could be a sign of 
disease persistence or relapse of PCa. Finally, in patients undergoing experimental therapies 
(e.g. immunotherapy), changes in the 
onndgenerati
onrdgenerati
2
3  PTH ratio could be evaluated as an 
efficacy measure. 
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Patient Sex Age Age at 
diagnosis 
Calcium 
(mmol/L)
PTH 
(ng/L) 
Creatinine 
(mg/L) 
Metastases 
(Y/N) 
Location of Metastases
1 F 59 42 3.69 736 11.1 Y Lung 
2 M 63 61 3.10 623 15.2 Y Lung 
3* M 36 31 2.89 860 8.8 Y Lymph node 
4 M 58 55 3.13 205 9.7 Y Mediastinum, lymph node, 
diaphragm, bone 
5* F 55 53 2.96 489 8.6 N  
6 F 65 60 4.62 718 9.7 N  
7 M 76 68 3.34 1277 9.2 Y Lung 
8 M 57 52 4.03 785 11.8 Y Lung 
9 M 55 49 3.47 350 11.4 Y Lung 
10 M 53 43 3.72 475 13.4 Y Mediastinum, bone 
11* M 70 62 3.40 137 11.8 N  
12 M 55 52 4.16 500 15.4 Y Lung 
13 F 66 60 4.30 230 8.3 Y Tracheostomy site 
14 F 58 51 4.10 1092 12.7 N  
15 M 62 55 2.74 223 17.3 Y N/A 
16 F 52 43 2.92 953 8.4 Y N/A 
17 F 42 28 4.56 723 21.2 Y Esophagus 
18 F 50 48 3.57 990 18.0 Y Left thyroid gland 
19 M 68 65 2.98 324 15.6 Y  
20 F 72 69 4.00 2471 4.0 Y Oesophagus 
21 M 77 68 2.92 357 37.4 N  
22 M 58 55 3.10 168 10.1 Y Liver 
23 F 35 34 4.85 1148 12.8 Y N/A 
 
Table 6: Clinical characteristics in 23 patients with advanced parathyroid cancer.  * patients with a 
normal 
onndgenerati
onrdgenerati
2
3
PTH ratio (<1); N/A: not available 
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Characteristics Result±standard deviation 
Sex 38% female 
Age (years) 65.2±16.5 
Mean vintage on hemodialysys  (in months) 88±71 
Serum creatinine (mg/L) 89±30 
2nd generation PTH (pg/mL) 244±247 
3rd generation PTH (pg/mL) 148±164 
Plasma calcium (mmol/L)  1.10±0.09 
 
 
Table 7: Characteristics of 73 hemodialysis patients used as comparator group  
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Characteristics Result±standard deviation 
Sex 45% female 
Age (years) 50.6±12.2 
Time elapsed since renal graft (in months) 56±49 
Serum creatinine (mg/L) 15.5±7.4 
2nd generation PTH (pg/mL) 90.2±57.6 
3rd generation PTH (pg/mL) 49.5±34.5 
Plasma calcium (mmol/L)  1.25±0.09 
 
 
Table 8: Characteristics of 60 renal transplant patients.  
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Inverted 
onndgenerati
onrdgenerati
2
3
PTH ratio (>1) Normal 
onndgenerati
onrdgenerati
2
3
PTH ratio (<1) 
Intact PTH 
(pg/mL) 
Whole PTH 
(pg/mL) 
Ratio Intact PTH 
(pg/mL) 
Whole PTH 
(pg/mL) 
Ratio 
261 435 1.66 814 668 0.82 
464 544 1.17 452 361 0.80 
188 333 1.77 695 438 0.63 
367 487 1.33    
1098 1363 1.24    
806 1101 1.37    
828 888 1.07    
606 768 1.27    
622 691 1.11    
185 370 2.00    
230 638 2.78    
71 99 1.40    
272 365 1.34    
363 583 1.61    
628 810 1.29    
404 542 1.34    
1063 1989 1.87    
197 358 1.82    
99 102 1.03    
747 1076 1.44    
Mean 
475 677 1.50 654 489 0.75 
 
 
Table 9: Individual and mean second generation and third generation PTH assays and the 
onndgenerati
onrdgenerati
2
3
PTH ratio in 23 patients with advanced parathyroid carcinoma 
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The determination of parathormone remains very difficult. Indeed, since the first assay 
developed by Rosalyn Yalow, our understanding of “what” is PTH and its implication in 
physiopathology, especially in CKD patients, has considerably evolved. 
The aim of our work was to provide a contribution to the study of parathormone, particularly 
in the light of a better pre-, post- and analytical management, as requested by the ISO 15189. 
Our contribution to the preanalytical phase of PTH determination is very important. Indeed, 
we have shown that the peptide is not very stable and that this stability depends on many 
factors, ie. the conservation temperature, the kind of tube used for the sampling, the 
automated method used for the determination and the patient himself.  
For the post-analytic phase, we have also provided useful information on the way that the 
reference range for PTH should be established. Based on these considerations, we have 
provided a methodology that allows a comprehensive interpretation of PTH results and that 
take into account the possible interferences due to rheumatoid factor or human anti-animal 
antibodies.  
For the analytic phase, and particularly in patients suffering from CKD, the choice of a 2nd vs. 
3rd generation kit is not obvious. Clearly, the recommendations of the K/DOQI are based on a 
2nd generation kit (Allegro), but are not easily transposable to the other 2nd generation kits. 
Recently, the KDIGO guidelines have been published. These guidelines are also based on 2nd 
generation kits but do not provide ‘raw values” anymore. This is a good point, but as they are 
based on the “laboratory’s published reference range”, they open the question on “what is a 
reference range” for PTH… 
The 3rd generation assays offer the advantage to be more easily “standardizable” then the 2nd  
generation ones, but are prone to the interference of the amino-PTH, which is only the case 
for the Roche Elecsys kit, a 2nd generation assays. Recently, Melamed et al have shown that 
the 3rd generation kits could be used as predictors of mortality in dialysis patients, but we need 
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more information and future studies are needed. A solution might perhaps be a 4th generation 
PTH, which would be free of the amino-PTH interference. Indeed, such a kit could be 
calibrated against an International standard and we would exactly know (unless we find a new 
PTH species, which is always possible!) what we assay. Nevertheless, even if this kit 
appeared on the market, prospective studies against bone biopsies would be needed (as well as 
clinical studies in patients with normal kidney function and various diseases, like 
hyperparathyroidism). This is also the main criticism that could be addressed to the use of 
bAP as a surrogate for PTH.  
Another point is that PTH determination is an important routine test. So, this new 4th 
generation kit should be available in every laboratory. It should not thus be an IRMA method 
(each lab is not necessarily allowed to manipulate isotopic methods), nor an ELISA method 
(which would be a regression). Thus, it should be an automated method. But then, what would 
happen to the labs that do not have this particular automate… 
Finally, we think that a prospective multicentric study in consecutive patients suffering from 
primary hyperparathyroidism that undergo surgery would be interesting to evaluate the 
onndgenerati
onrdgenerati
2
3 PTH ratio. 
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